<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10748411</article-id><article-id pub-id-type="pmcid-ver">PMC10748411.1</article-id><article-id pub-id-type="pmcaid">10748411</article-id><article-id pub-id-type="pmcaiid">10748411</article-id><article-id pub-id-type="pmid">38143497</article-id><article-id pub-id-type="doi">10.3389/fphar.2023.1292088</article-id><article-id pub-id-type="publisher-id">1292088</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Recent progress in the role of endogenous metal ions in doxorubicin-induced cardiotoxicity</article-title><alt-title alt-title-type="left-running-head">Zhou et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2023.1292088" ext-link-type="uri">10.3389/fphar.2023.1292088</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="N">Ni</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="S">Shanshan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="T">Taoli</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xie</surname><given-names initials="S">Suifen</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="J">Jian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="W">Wenqun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/529164/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="B">Bikui</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/506861/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Pharmacy</institution>, <institution>The Second Xiangya Hospital</institution>, <institution>Central South University</institution>, <addr-line>Changsha</addr-line>, <addr-line>Hunan</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Institute of Clinical Pharmacy</institution>, <institution>Central South University</institution>, <addr-line>Changsha</addr-line>, <addr-line>Hunan</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>School of Pharmacy</institution>, <institution>Central South University</institution>, <addr-line>Changsha</addr-line>, <addr-line>Hunan</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>School of Pharmacy</institution>, <institution>Hunan University of Chinese Medicine</institution>, <addr-line>Changsha</addr-line>, <addr-line>Hunan</addr-line>, <country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/70087/overview" ext-link-type="uri">Irena Kostova</ext-link>, Medical University Sofia, Bulgaria</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/920880/overview" ext-link-type="uri">Amany Mohammed Gad</ext-link>, Sinai University, Egypt</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2537716/overview" ext-link-type="uri">Aleksandar Djordjevic</ext-link>, University of Novi Sad, Serbia</p></fn><corresp id="c001">*Correspondence: Wenqun Li, <email>liwq1204@csu.edu.cn</email>; Bikui Zhang, <email>505995@csu.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427358</issue-id><elocation-id>1292088</elocation-id><history><date date-type="received"><day>11</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>23</day><month>12</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-18 13:25:10.843"><day>18</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Zhou, Wei, Sun, Xie, Liu, Li and Zhang.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Zhou, Wei, Sun, Xie, Liu, Li and Zhang</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-14-1292088.pdf"/><abstract><p>Doxorubicin is a widely used anticancer drug in clinical practice for the treatment of various human tumors. However, its administration is associated with cardiotoxicity. Administration of doxorubicin with low side effects for cancer treatment and prevention are, accordingly, urgently required. The human body harbors various endogenous metal ions that exert substantial influences. Consequently, extensive research has been conducted over several decades to investigate the potential of targeting endogenous metal ions to mitigate doxorubicin&#8217;s side effects and impede tumor progression. In recent years, there has been a growing body of research indicating the potential efficacy of metal ion-associated therapeutic strategies in inhibiting doxorubicin-induced cardiotoxicity (DIC). These strategies offer a combination of favorable safety profiles and potential clinical utility. Alterations in intracellular levels of metal ions have been found to either facilitate or mitigate the development of DIC. For instance, ferroptosis, a cellular death mechanism, and metal ions such as copper, zinc, and calcium have been identified as significant contributors to DIC. This understanding can contribute to advancements in cancer treatment and provide valuable insights for mitigating the cardiotoxic effects of other therapeutic drugs. Furthermore, potential therapeutic strategies have been investigated to alleviate DIC in clinical settings. The ultimate goal is to improve the efficacy and safety of Dox and offer valuable insights for future research in this field.</p></abstract><kwd-group><kwd>doxorubicin</kwd><kwd>cardiotoxicity</kwd><kwd>iron</kwd><kwd>copper</kwd><kwd>zinc</kwd><kwd>calcium</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>Fundamental Research Funds for Central Universities of the Central South University
</institution><institution-id institution-id-type="doi">10.13039/501100012476</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn003"><institution-wrap><institution>Natural Science Foundation of Hunan Province
</institution><institution-id institution-id-type="doi">10.13039/501100004735</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn004"><institution-wrap><institution>Health and Family Planning Commission of Hunan Province
</institution><institution-id institution-id-type="doi">10.13039/501100010451</institution-id></institution-wrap></funding-source></award-group><award-group><funding-source id="cn005"><institution-wrap><institution>Chinese Pharmaceutical Association
</institution><institution-id institution-id-type="doi">10.13039/501100004433</institution-id></institution-wrap></funding-source></award-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants of the National Natural Scientific Foundation of China (Nos 82173911 and 81973406), Fundamental Research Funds for the Central Universities of Central South University (No. 2023ZZTS0891), Hunan Provincial Natural Scientific Foundation (Nos 2023JJ30761 and 2023JJ30802), Scientific Research Project of Hunan Provincial Health and Family Planning Commission (No. 202113050843), and Research Project established by Chinese Pharmaceutical Association Hospital Pharmacy department (No. CPA-Z05-ZC-2021-002).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pharmacology of Anti-Cancer Drugs</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>1 Introduction</title><p>Doxorubicin (Dox), the first anthracycline used in clinical therapy, is a widely used class of antitumor antibiotics, commonly employed in the treatment of childhood leukemia, breast cancer, lymphoma, and sarcoma, among other conditions. Unfortunately, the clinical application of Dox in anticancer therapy is greatly limited by various systemic adverse reactions, which can lead to acute and chronic cardiomyopathy and, in severe cases, congestive heart failure, and the cardiotoxicity is considered irreversible (<xref rid="B39" ref-type="bibr">Ewer and Lippman, 2005</xref>). DIC is classified as acute and chronic, the clinical dose of Dox is 50&#8211;60&#160;mg once every 3&#8211;4&#160;weeks or 20&#8211;30&#160;mg weekly for 3&#160;weeks, repeated after 2&#8211;3&#160;weeks of withdrawal, with a maximum cumulative dose of 550&#160;mg/m<sup>2</sup> (<xref rid="B85" ref-type="bibr">Li and Hill, 2014</xref>). Children&#8217;s dosage is about half that of an adult. Up to 25% of patients using Dox may experience DIC (<xref rid="B123" ref-type="bibr">Swain et al., 2003</xref>).</p><p>Dox inhibits the growth and proliferation of tumor cells by inhibiting topoisomerase II (Top2&#946;), inserting into the double helix structure of DNA to unravel the double strand and inhibiting DNA and RNA synthesis (<xref rid="B80" ref-type="bibr">Kitakata et al., 2022</xref>). However, the exact mechanism of DIC is not fully deciphered, and it is only certain that oxidative stress and apoptosis play a key role in DIC. Numerous studies have identified various potential pathogenic mechanisms of DIC, including transcriptional dysregulation, calcium dysregulation, oxidative stress, DNA damage, nitric oxide release, inflammatory mediates, mitochondrial dysfunction, accumulation of iron in mitochondria, and dysregulation of autophagy due to the inhibition of Top2&#946; (<xref rid="B118" ref-type="bibr">Renu et al., 2018</xref>). Therefore, it is important and advantageous to gain an understanding of the pathological factors that contribute to the onset or progression of DIC.</p><p>The human body needs trace elements such as iron, copper, zinc, calcium, manganese, etc., to maintain health and normal function of the system. These essential metal elements play a crucial role within cells, as many catalytic enzymes and proteins involved in biochemical processes heavily depend on them (<xref rid="B155" ref-type="bibr">Zoroddu et al., 2019</xref>). Disorders in iron metabolism can result in significant tissue degeneration, impairment of organ function, and potential development of cancer, ferroptosis activation may be a potential strategy to overcome mechanisms of resistance to conventional cancer therapy (<xref rid="B152" ref-type="bibr">Zhao et al., 2022</xref>). In mice mesothelioma models, reducing bioavailable copper through the use of D-pen, tetrathiomolybdate (TM), or trientine also reduced tumor growth and hindered tumor blood vessel formation (<xref rid="B63" ref-type="bibr">Ishida et al., 2013</xref>). Zinc can bind to Tau-specific amino acids to accelerate deposition, induce Tau abnormal phosphorylation, amplify its cytotoxicity, and aggravate cognitive impairment in Alzheimer&#8217;s patients (<xref rid="B58" ref-type="bibr">Hu et al., 2017</xref>). Calcium is chelated through the sarcoplasmic/endoplasmic Ca<sup>2+</sup>-ATPase (SERCa2a) after its release from the Ryanodine receptors (RyR2), and changes in these proteins in the circulation occur as the heart ages, leading to arrhythmias (<xref rid="B55" ref-type="bibr">Hamilton and Terentyev, 2019</xref>).</p><p>The disturbance of metal ion balance in cardiomyocyte of DIC patients is associated with oxidative stress and mitochondrial dysfunction, indicating the significant role of metal ions in the pathogenesis of DIC (<xref rid="B120" ref-type="bibr">Sheibani et al., 2022</xref>). In heart tissues affected by DIC, it is possible to observe alterations in the regulation of metal ions, including upregulation, downregulation, or dysregulation. In 2022, Abe et al. found that Dox accumulated in mitochondria by intercalating into mitochondrial DNA and decreased the abundance of 5&#8242;-aminolevulinate synthase 1, the rate-limiting enzyme in this process, thereby resulting in iron overload and ferroptosis in mitochondria in cultured cardiomyocytes (<xref rid="B1" ref-type="bibr">Abe et al., 2022</xref>). Clinical trials have been conducted in experimental animal models of DIC, using supplementation, chelation, or modulation of metal ions for treatment.</p><p>In the following section, we have reviewed the various roles of metal ions in the pathological mechanism of DIC and have discussed the roles of iron, copper, zinc, and calcium in triggering oxidative stress, mitochondrial dysfunction, DNA damage, among other effects.</p></sec><sec id="s2"><title>2 Role and mechanism of ferroptosis in DIC</title><p>Ferroptosis is a newly discovered mode of regulatory cell death (RCD) by Stockwell et al., in 2002. Unlike other RCD modes. Ferroptosis does not show apoptotic features such as nuclear rupture, DNA ladder, and caspase-3 activation (<xref rid="B34" ref-type="bibr">Dolma et al., 2003</xref>), instead, it relies on Fe<sup>2+</sup> and reactive oxygen species (ROS), along with mitochondrial dysfunction. This dysfunction is observed as mitochondrial outer membrane rupture, reduction or disappearance of mitochondrial ridges and shrinkage of the mitochondrial membrane (<xref rid="B47" ref-type="bibr">Friedmann Angeli et al., 2014</xref>). By focusing on the three primary features of ferroptosis, namely, dependence on iron, disrupted lipid metabolism, and excessive production of ROS (<xref rid="B66" ref-type="bibr">Jiang et al., 2021</xref>), new therapeutic targets can be pinpointed and more precise drugs can be developed. These are illustrated in <xref rid="F1" ref-type="fig">Figure 1</xref>.</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Mechanism of ferroptosis induced by Doxorubicin. Interference with iron metabolism after Dox administration, leads to DNA damage and endoplasmic reticulum stress, impairing mitochondrial function, ultimately resulting in cardiac toxicity. Blunt-ended lines indicate inhibition while arrows indicate promotion; DOX Doxorubicin; Top &#8545; topoisomerase &#8545;; SER sarcoplasmic (endoplasmic) reticulum; FPN ferroportin; DMT1 divalent metal-ion transporter 1; TfR1 transferrin receptor 1; GLS glutaminase; GSH glutathione; GSSG glutathione disulfide; GPX4 glutathione peroxidase 4; GSR glutathione reductase; NADPH nicotinamide adenine dinucleotide phosphate; AMPK AMP-activated protein kinase; PGC1&#945; peroxisome proliferator&#8211;activated receptor-gamma coactivator 1&#945;; TGF &#946; transforming growth factor &#946;; ULK1 Unc-51 like autophagy activating kinase; mTOR mammalian target of rapamycin. Image from biorender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-14-1292088-g001.jpg"/></fig><sec id="s2-1"><title>2.1 Iron overload</title><p>There are two main sources of dietary iron absorption: inorganic iron and heme iron (<xref rid="B132" ref-type="bibr">Uzel and Conrad, 1998</xref>). In a study conducted by Panjrath, G. S. et al., two groups of animals were fed either iron-rich food or ordinary food, and then treated with Dox and normal saline, respectively. The results showed that animals fed iron-rich food exhibited more severe DIC compared to those fed ordinary food. Additionally, feeding iron-rich foods alone did not cause cardiac damage, suggesting that iron accumulation and its bioavailability in the body may serve as crucial independent predictors of DIC sensitivity (<xref rid="B109" ref-type="bibr">Panjrath et al., 2007</xref>). The deposition of iron in cardiomyocyte can result in oxidative stress, mitochondrial damage and dysfunction, which further worsens DIC.</p><p>Disruption of the redox equilibrium is a core pathological mechanism in many heart diseases. The conversion of Fe<sup>3+</sup> to Fe<sup>2+</sup> is a reversible redox process, but electron transfer may result in the production of excessive ROS when iron is overloaded in cardiomyocyte. Normally, there is not enough free iron in the body to bind with Dox, the problem is that Dox carries a positive charge which enhances its affinity for iron and promotes the formation of the Dox-Fe complex. This complex alters the distribution and metabolism of iron and further combines with free oxygen in the body, resulting in cardiotoxicity (<xref rid="B54" ref-type="bibr">Gutteridge, 1984</xref>). Furthermore, iron and copper ions promote the binding of Dox to DNA, leading to increased cytotoxicity. A study demonstrated that 5-fluorouracil can upregulate iron levels in animals and cause iron accumulation in cell experiments, resulting in fluorescence quenching and increasing lipid peroxide levels (<xref rid="B87" ref-type="bibr">Li et al., 2022a</xref>). In addition, a study by He et al. revealed that pretreatment with Epigallocatechin-3-gallate can reduce iron deposition, inhibit oxidative stress by activating AMPK&#945;2 (<xref rid="B56" ref-type="bibr">He et al., 2021</xref>). Recent studies have also shown that cardiac dysfunction caused by ferroptosis can be inhibited by iron complexing agents and antioxidants such as Ferrostatin-1 (<xref rid="B11" ref-type="bibr">Baba et al., 2018</xref>), Dexrazoxane (<xref rid="B142" ref-type="bibr">Weiss et al., 1999</xref>), Deferoxamine (<xref rid="B101" ref-type="bibr">Menon and Kim, 2022</xref>), Deferiprone (<xref rid="B37" ref-type="bibr">El-Ammar el et al., 2011</xref>), and Vitamin E (<xref rid="B15" ref-type="bibr">Berthiaume et al., 2005</xref>). These studies demonstrate that iron overload exacerbates Dox-induced oxidative stress and cardiomyocyte death. Interestingly, the use of antioxidants alone is insufficient to protect against DIC (<xref rid="B105" ref-type="bibr">Mukhopadhyay et al., 2009</xref>).</p><p>Cardiomyocyte contain a large number of mitochondria (<xref rid="B120" ref-type="bibr">Sheibani et al., 2022</xref>). However, mitochondria are also prone to iron overload, leading to lipid peroxidation on their membranes. Li et al. discovered that injection of endotoxin into mice increases the expression of nuclear receptor coactivator 4, facilitating the transfer of Fe<sup>3+</sup> to mitochondria, leading to mitochondrial iron overload, triggering oxidative stress (<xref rid="B89" ref-type="bibr">Li et al., 2020b</xref>). On the other hand, Chang H.C. et al. suggested that overexpression of the mitochondrial iron efflux pump or the application of specifically targeted iron chelating agents within mitochondria could decrease mitochondrial iron levels (<xref rid="B22" ref-type="bibr">Chang et al., 2016</xref>). For instance, MitoTEMPO, a mitochondria-targeting antioxidant, can be easily integrated into the mitochondria (<xref rid="B32" ref-type="bibr">Dikalova et al., 2010</xref>). Experimental results have demonstrated that mitochondrial oxidative damage is the primary mechanism of heart injury caused by ferroptosis. Interestingly, the non-targeted antioxidant TEMPO does not exhibit any cardiac protective effects (<xref rid="B41" ref-type="bibr">Fang et al., 2019</xref>). Similarly, Ichikawa et al. confirmed that overexpression of the mitochondrial transporter ABCB8 promotes iron efflux, and prevents DIC <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> (<xref rid="B62" ref-type="bibr">Ichikawa et al., 2014</xref>). This suggests that reducing the iron levels in cardiomyocyte mitochondria can reverse the cardiotoxicity caused by Dox in cancer therapy.</p></sec><sec id="s2-2"><title>2.2 Ferroptosis regulatory pathway</title><sec id="s2-2-1"><title>2.2.1 Glutathione peroxidase 4 (GPX4)</title><p>The enzyme selenate Gpx4 plays a crucial role in regulating ferroptosis by minimizing lipid peroxidation. It accomplishes this by converting reduced glutathione (GSH) into glutathione disulfide (GSSG) and utilizing hydrogen ions to effectively diminish the presence of hydrogen peroxide and lipid peroxidation, subsequently reducing the accumulation of ROS (<xref rid="B45" ref-type="bibr">Forcina and Dixon, 2019</xref>). Several studies have reported that Dox can attenuate the levels of Gpx4. Protein arginine methyltransferase 4 can inhibit the Nrf2/Gpx4 to enhance ferroptosis, then mitigate DIC (<xref rid="B140" ref-type="bibr">Wang et al., 2022c</xref>). Moreover, the overexpression of Gpx4 or the introduction of ferrous ion chelators specifically targeting mitochondria have demonstrated the ability to mitigate DIC (<xref rid="B125" ref-type="bibr">Tadokoro et al., 2020</xref>).</p></sec><sec id="s2-2-2"><title>2.2.2 GSH/GSSG</title><p>GSH, a tripeptide comprising glutamine, cysteine and glycine, exists in cells in either its oxidized form, GSSG, or reduced form, GSH. GSH/GSSG is influenced by redox reaction, and maintaining an optimal ratio is vital for combating oxidative stress (<xref rid="B5" ref-type="bibr">Anderson, 1998</xref>). GSH catalytic detoxification of various electrophilic compounds and peroxides, facilitating the elimination of ROS through the, a process mediated by glutathione S-transferase and Gpx enzymes (<xref rid="B128" ref-type="bibr">Townsend et al., 2003</xref>). In a study conducted by Sun et al. observed that the protein expression of Gpx4 and SLC7A11, as well as the GSH/GSSG, were diminished upon Herceptin treatment (<xref rid="B121" ref-type="bibr">Sun et al., 2022</xref>). Furthermore, the intervention of Herceptin resulted in an increase in cellular and mitochondrial iron levels (<xref rid="B121" ref-type="bibr">Sun et al., 2022</xref>).</p></sec><sec id="s2-2-3"><title>2.2.3 System Xc-</title><p>System Xc-is a heterodimer reverse transport system for input cysteine and output glutamate, consisting of two subunits SLC3A2 and SLC7A11. Among them, SLC7A11 can promote cystine uptake and glutathione biosynthesis, maintain redox balance <italic toggle="yes">in vivo</italic>, and inhibit ferroptosis (<xref rid="B75" ref-type="bibr">Kim et al., 2020</xref>). In addition, the expression level of SLC7A11 is usually positively correlated with the activity of the reverse transporter (<xref rid="B84" ref-type="bibr">Lewerenz et al., 2013</xref>). Activation of transcription factor 3 (ATF3), a common stress receptor, inhibits SLC7A11 expression, thereby exacerbating elastin-induced lipid peroxidation and ferroptosis (<xref rid="B135" ref-type="bibr">Wang et al., 2020a</xref>). Repression of the SLC7A11/GSH/GPX4 axis triggers ferroptosis of vascular smooth muscle cells to promote vascular calcification under chronic kidney disease conditions (<xref rid="B146" ref-type="bibr">Ye et al., 2022</xref>).</p></sec><sec id="s2-2-4"><title>2.2.4 Nrf2-KEAP1</title><p>Nuclear factor erythroid 2-related factor 2 (Nrf2) possesses redox activity, when activated, iit enhances the overall detoxification and clearance of harmful substances in cells. Keap1 serves as an adapter protein for the CUL3-based E3 ubiquitin ligase and, under normal circumstances, binds to cytoplasmic Nrf2, promoting its ubiquitination and degradation. Hence, Keap1 functions as a negative inhibitor of Nrf2, a proposition that has also been experimentally supported through gene-deficient mice. Tertbutylhydroquinone (tBHQ) is an Nrf2 activator (<xref rid="B33" ref-type="bibr">Dinkova-Kostova and Talalay, 2008</xref>), the research demonstrates that tBHQ can induce Nrf2 overexpression, resulting in the upregulation of SLC7A11 expression in Hela or human corneal endothelial cells (<xref rid="B52" ref-type="bibr">Guha and Roy, 2021</xref>). In transgenic mice models, it has been proven that sequestration of Keap1 has been found to protect the heart from doxorubicin-induced ferroptosis (<xref rid="B57" ref-type="bibr">Hou et al., 2021</xref>). The ubiquitin E3 ligase TRIM21 interacts with p62 and ubiquitinates it, negatively regulating the p62-KEAP1-Nrf2 antioxidant pathway (<xref rid="B116" ref-type="bibr">Refaie et al., 2021</xref>).</p></sec><sec id="s2-2-5"><title>2.2.5 AMPK</title><p>Adenosine monophosphate-activated protein kinase (AMPK) is a macromolecular protein complex composed of three subunits: one catalytic site &#945; and two regulatory sites &#946; and &#947;. The AMPK pathway is closely associated with key mechanisms of DIC, including oxidative stress, mitochondrial damage, dysregulation of autophagy, increased apoptosis, and fibrosis. Dox inhibits the activation of other signals such as Akt and mitogen activated protein kinase (MAPK) through the AMPK pathway, leading to DNA damage. Activation of AMPK has several effects: firstly, it inhibits the autophagy activating protein ULK1, promoting autophagy (<xref rid="B77" ref-type="bibr">Kim et al., 2011</xref>); secondly, it inhibits the TGF&#946; pathway, which decreases myocardial fibrosis (<xref rid="B90" ref-type="bibr">Lin et al., 2015</xref>); thirdly, it inhibits the mTOR signal, reducing apoptosis (<xref rid="B117" ref-type="bibr">Ren et al., 2016</xref>). Various drugs can activate the AMPK signal, including metformin, statins, resveratrol, thiazolidinedione, AICAR (Acadesine), and specific AMPK agonists. These drugs are expected to have clinical applications in resisting DIC.</p></sec></sec></sec><sec id="s3"><title>3 Promotion and treatment strategy of copper on DIC</title><p>Copper, an essential trace element in basic physiological activities of the human body, is involved in numerous key biological processes, including free radical scavenging, iron metabolism, connective tissue synthesis, immunity and cell signal transduction (<xref rid="B126" ref-type="bibr">Tainer et al., 1983</xref>; <xref rid="B13" ref-type="bibr">Banci and Bertini, 2013</xref>; <xref rid="B8" ref-type="bibr">Apresova et al., 2014</xref>; <xref rid="B16" ref-type="bibr">Bhuvanasundar et al., 2014</xref>). Additionally, several important &#8220;cuproproteins&#8221; in the human body, such as cytochrome C oxidase (COX), NADH dehydrogenase-2, Cu/Zn-superoxide dismutase (SOD1) and tyrosinase, rely on copper as a catalytic cofactor to fulfill their roles (<xref rid="B31" ref-type="bibr">Denoyer et al., 2015</xref>). Furthermore, the high redox activity of copper allows it to easily transition between the two valence states, and as a result, the generated electrons can promote the formation of ROS (<xref rid="B113" ref-type="bibr">Purchase, 2013</xref>).</p><p>In patients with osteosarcoma and leukemia, endogenous copper levels are higher compared to normal cells and tissues, and patients with more aggressive typically exhibit elevated serum copper levels (<xref rid="B44" ref-type="bibr">Fisher et al., 1976</xref>). Copper has been shown to promote angiogenesis, tumor growth, and metastasis (<xref rid="B53" ref-type="bibr">Gupte and Mumper, 2009</xref>). The body regulates copper concentrations through processes of absorption, excretion and bioavailability. Copper obtained from food sources (organic copper) undergoes processing by the liver, which controls its distribution in serum and tissues, excretes excess copper into bile (<xref rid="B6" ref-type="bibr">Angelova et al., 2011</xref>); on the other hand, copper (inorganic copper) present in drinking water or from copper supplements is absorbed by the intestinal mucosa and directly enters the free copper pool in the blood, bypassing the liver. This route likely allows copper to cross the blood-brain barrier (BBB) (<xref rid="B18" ref-type="bibr">Brewer, 2009</xref>). Based on <xref rid="F2" ref-type="fig">Figure 2</xref>, three main approaches can be identified for addressing copper overload.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Intracellular transport of copper and the mechanism of chelating agents, ionophores, and complexes. The Cu<sup>2+</sup> is reduced to Cu<sup>+</sup>, which then enters myocardial cells and binds to different proteins to maintain a steady state of copper ions in the cytoplasm. When there is an overload of copper ions, they can be removed by copper chelators, copper ionophores, and copper coordination compounds, which have a protective effect by clearing free copper ions. GSH glutathione; COX17 cytochrome c oxidase copper chaperone; ATOX1 antioxidant protein; CCS copper chaperone for SOD1; SOD Cu/Zn-superoxide dismutase; MT metallothionein; Ctr1 copper transporter 1; LOX recombinant lysyl oxidase; COX cytochrome c oxidase; MEK1/2 mitogen-activated protein kinase kinase; NF-&#954;B nuclear factor kappa-B; VEGF vascular endothelial growth factor; FGF2 human basic fibroblast growth factor 2; ATP7A/B copper transporting ATPase A/B. Image from biorender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-14-1292088-g002.jpg"/></fig><p>Copper deficiency may not necessarily worsen the cardiac toxicity induced by Dox (<xref rid="B43" ref-type="bibr">Fischer et al., 1993</xref>). It was found that copper-deficient rats may compensate for Dox-induced oxidative stress in the heart by improving the activity of Cu, Zn-superoxide dismutase and glutathione S-transfers (<xref rid="B42" ref-type="bibr">Fischer et al., 1992</xref>). However, Mizutani, H. et al. measured the levels of 8-oxo-7,8-dihydro-2&#8242;-deoxyguanosine (8-oxodG), a marker of DNA damage, and found that Dox can cause DNA damage in the presence of Cu<sup>2+</sup> or cytochrome P450 reductase. Curiously, the extent of Cu<sup>2+</sup>-mediated DNA damage, including the formation of 8-oxodG, is far greater than the extent of DNA damage mediated by cytochrome P450 reductase (<xref rid="B103" ref-type="bibr">Mizutani et al., 2003</xref>). Therefore, people are striving to maintain stable levels of copper within cells when using Dox. This is currently being done through three approaches: chelation, ion carriers, and coordination compounds.</p><sec id="s3-1"><title>3.1 Copper chelation</title><p>The use of copper chelators to reduce the concentration and bioavailability of copper <italic toggle="yes">in vivo</italic> is an effective method. By forming complexes with copper, chelators help remove it from the body and inhibit the formation of cancer blood vessels, thereby preventing further progression of the disease.</p><p>Several common copper chelators, such as D-pen, trientine, ALXN 1840, or TM, have been shown to delay the spread of cancer by inhibiting angiogenesis in various animal models. This effect has been demonstrated in animal models of rat gliosarcoma (<xref rid="B17" ref-type="bibr">Brem et al., 1990</xref>), mice hepatocellular carcinoma (<xref rid="B147" ref-type="bibr">Yoshii et al., 2001</xref>), head and neck squamous cell carcinoma (<xref rid="B28" ref-type="bibr">Cox et al., 2001</xref>) and mesothelioma (<xref rid="B29" ref-type="bibr">Crowe et al., 2013</xref>). D-PEN, for example, can inhibit the activity of lysine oxidase and disrupt collagen crosslinking. Consequently, it affects the expression of endothelial growth factor, leading to the delayed progression of glioblastoma multiforme <italic toggle="yes">in vivo</italic> (<xref rid="B96" ref-type="bibr">Mammoto et al., 2013</xref>). Animal experiments have shown that treatment with trientine at doses ranging from approximately 34&#8211;68&#160;mg/kg/day for 6&#8211;8&#160;weeks resulted in increased cardiac output, increased left ventricular pressure, as well as improvements in left ventricular fractional shortening (LVFS) and left ventricular ejection fraction (LVEF). TM-induced copper deficiency inhibits angiogenesis by activating the transcription factor NF-&#954;B, thereby reducing the secretion of angiogenic factors (VEGF, FGF2) and interleukins (IL-1a, IL-6, IL-8) (<xref rid="B110" ref-type="bibr">Pan et al., 2003</xref>). ALXN1840 acts by forming a tripartite complex with copper and albumin, which reduces the levels of non-ceruloplasmin-bound copper in the bloodstream. It specifically targets intracellular copper in the liver and increases the copper excretion through bile (<xref rid="B81" ref-type="bibr">Komatsu et al., 2000</xref>).</p></sec><sec id="s3-2"><title>3.2 Copper ionophore</title><p>Copper ionophores are a class of fat-soluble molecules that reversibly bind copper ions and can induce apoptosis in copper-containing cells. Unlike copper chelators, which remove copper from the body, copper ionophores redistribute the distribution of copper ions within cells. By doing so, they exploit the cytotoxicity of copper to specifically target and eliminate cancer cells.</p><p>Three different compounds&#8212;Cu<sup>2+</sup>(gtsm) (a bis(thiosemicarbazone) analog), clioquinol (a hydroxyquinoline analog) and disulfiram (a dithiocarbamate analog)&#8212;have been studied for their ability to inhibit proteasomal chymotrypsin-like activity, thereby preventing the release of copper (<xref rid="B24" ref-type="bibr">Chen et al., 2007</xref>). These compounds have demonstrated anticancer effects both <italic toggle="yes">in vitro</italic> and in rodent models (<xref rid="B21" ref-type="bibr">Cater et al., 2013</xref>). Cu<sup>2+</sup>(gtsm), when used in combination with its ligands, exhibited enhanced anti-proliferative activity against tumor cells compared to the ligands alone (<xref rid="B7" ref-type="bibr">Anjum et al., 2019</xref>). It is worth noting that the growth of tumors in an anoxic microenvironment diminishes the anti-proliferative efficacy of most bis(thiosemicarbazone) compounds and their copper complexes, compared to an oxygen-rich environment (<xref rid="B7" ref-type="bibr">Anjum et al., 2019</xref>). Clioquinol and disulfiram have undergone extensive clinical trials, the results have shown that these compounds can indeed transport copper into human cells and exert selective cytotoxicity in tumor cells. However, the underlying reasons for this selectivity have not been identified (<xref rid="B69" ref-type="bibr">Johansson, 1992</xref>; <xref rid="B119" ref-type="bibr">Schimmer et al., 2012</xref>). Studies have demonstrated that the anticancer activity of clioquinol is intensified with higher extracellular copper levels, which can be counteracted by the formation of copper complexes with a chelating agent called TM (<xref rid="B20" ref-type="bibr">Cater and Haupt, 2011</xref>). Li et al.'s study showed that the disulfiram-copper complex exerts anti-tumor activity in nasopharyngeal carcinoma cells through the ROS/MAPK pathway and the p53-mediated ferroptosis pathway. Additionally, this complex can inhibit &#945;-SMA expression, inactivate cancer-related fibroblasts (<xref rid="B94" ref-type="bibr">Li et al., 2020c</xref>).</p></sec><sec id="s3-3"><title>3.3 Copper coordination compounds</title><p>The interest in finding alternative metal complexes for supplementary treatment has been growing, considering the widespread clinical use of platinum-based drugs such as cisplatin, carboplatin, and oxaliplatin. This is driven by the aim of reducing the side effects associated with platinum-containing chemotherapy (<xref rid="B97" ref-type="bibr">Marzano et al., 2009</xref>). Copper has been shown to have potential to enhance efficacy, reduce side effects, and bypass drug resistance (<xref rid="B97" ref-type="bibr">Marzano et al., 2009</xref>). A study conducted by Pivetta evaluated the combined effects of three copper coordination compounds containing one or two 1,10-phenanthroline molecules in combination with cisplatin. The results indicated a significant synergistic anti-tumor effect on cell proliferation. This combination therapy holds promise for enhancing the effectiveness of existing treatments (<xref rid="B111" ref-type="bibr">Pivetta et al., 2015</xref>). Additionally, the combination of copper and tin binary complexes has been investigated, demonstrating superior anticancer activity compared to monometallic complexes (<xref rid="B23" ref-type="bibr">Chauhan et al., 2007</xref>). CuSn2 has been particularly effective in inducing apoptotic cell death in various cancer cell lines <italic toggle="yes">in vitro</italic>. Notably, CuSn2 exhibits a significantly higher maximum tolerated dose than cisplatin while causing fewer toxic side effects. Interestingly, there is no evidence of liver, kidney, or brain toxicity associated with CuSn2 at equivalent doses (<xref rid="B148" ref-type="bibr">Zaidi et al., 2014</xref>).</p><p>In conclusion, the increasing research on copper complexes as complementary chemotherapy agents presents an encouraging avenue for cancer treatment. Novel copper complexes, such as the binuclear Cu<sup>2+</sup> complex targeting DNA, combinations with existing drugs like cisplatin, and heterologous copper-tin complexes, hold promise for future cancer therapies. Further studies are warranted to fully explore the efficacy and safety profiles of these complexes and their potential for clinical translation.</p></sec></sec><sec id="s4"><title>4 Regulation of zinc and promoting effect on DIC and potential therapeutic direction</title><p>Zinc is the second most abundant metal element in the human body after iron. The majority of enzymatic reactions in the human body rely on zinc, making it indispensable for normal physiological functions and overall health. Zinc is found in various tissues and organs, but its content in the heart is minimal, accounting for 0.4% of the total zinc content (<xref rid="B78" ref-type="bibr">King et al., 2000</xref>). With age and the presence of certain pathological conditions, the level of zinc in the body gradually decreases, leading to an increased risk of complications (<xref rid="B14" ref-type="bibr">Bay&#305;r et al., 2013</xref>). Decreased zinc ion concentration in peripheral blood has been suggested as an independent risk factor for predicting coronary heart disease, especially in elderly patients, non-smokers, and postmenopausal women (<xref rid="B100" ref-type="bibr">Meng et al., 2021</xref>).</p><p>The [Zn<sup>2+</sup>]<sub>i</sub> in Dox-treated H9c2 cells is significantly higher compared to the control group, indicating the presence of endoplasmic reticulum (ER) stress as evidenced by elevated levels of ER stress markers, such as GRP78 and CHOP/Gadd15 (<xref rid="B107" ref-type="bibr">Olgar et al., 2018</xref>). Interestingly, directly increasing [Zn<sup>2+</sup>]<sub>i</sub> through a zinc ion carrier induced a significant increase in these markers, while directly inducing ER stress did not alter the levels of zinc ion transport proteins (<xref rid="B107" ref-type="bibr">Olgar et al., 2018</xref>). Disruption of Zn<sup>2+</sup> homeostasis in cells can lead to mitochondrial and endoplasmic reticulum stress, causing disruption of normal ER/mitochondrial crosstalk and mitochondrial autophagy, resulting in metabolic dysfunction (<xref rid="B30" ref-type="bibr">Dabravolski et al., 2022</xref>). Therefore, controlling intracellular zinc levels through zinc ion transporters may be an important approach in the treatment of DIC.</p><sec id="s4-1"><title>4.1 Zinc ion transporters</title><p>Zinc homeostasis is regulated by multiple proteins at various levels. Zinc ion transporters are the most significant among these regulators, which can be classified into two families: ZnTs (SLC30) and ZIPs (SLC39) (<xref rid="B71" ref-type="bibr">Kambe et al., 2021</xref>), as shown in <xref rid="F3" ref-type="fig">Figure 3</xref>. The ZIPs family increases zinc ion concentration in the cytoplasm by promoting extracellular uptake or release from subcellular organelles. Conversely, the ZnTs family reduces zinc ion concentration in the cytoplasm. Imbalances or changes in the expression and localization of these zinc ion transporters can lead to zinc ion imbalances, resulting in various severe pathophysiological stimuli within cells (<xref rid="B129" ref-type="bibr">Tuncay et al., 2019</xref>). The expression of zinc ion transporters ZIP7 and ZnT7 at the protein and RNA levels is relatively low in mammalian heart tissues. ZIP7 is widely expressed in human and mice tissues, while ZnT7 is abundant in the liver and small intestine (<xref rid="B79" ref-type="bibr">Kirschke and Huang, 2003</xref>; <xref rid="B59" ref-type="bibr">Huang et al., 2005</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Zinc is maintained by two families, ZnTs and ZIPs. There are two families of zinc transport proteins that maintain the stability of zinc ions within the body. ZIPs (SLC39A) increase the concentration of zinc in the cytoplasm, while ZnTs (SLC30A) decrease the concentration of zinc in the cytoplasm. Image from biorender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-14-1292088-g003.jpg"/></fig><p>Kirschke et al. and Turan et al. analyzed confocal images of cardiomyocyte using immunofluorescence microscopy and Huygens software, they found that ZIP7 was primarily located in the sarcoplasmic(endoplasmic) reticulum [S(E)R], with a small portion in the Golgi apparatus, but not in the nucleus(<xref rid="B79" ref-type="bibr">Kirschke and Huang, 2003</xref>; <xref rid="B131" ref-type="bibr">Turan, 2019</xref>). Similarly, Tuncay et al. examined ZIP7 and ZnT7 colocalization in S(E)R preparations isolated from rat cardiomyocyte and observed the same localization pattern (<xref rid="B130" ref-type="bibr">Tuncay et al., 2017</xref>). They also discovered that hyperglycemia-induced intracellular redistribution of free zinc led to an increased cytoplasmic [Zn<sup>2+</sup>]<sub>i</sub> and decreased [Zn<sup>2+</sup>]<sub>i</sub> in S(E)R through activation of CK2&#945;-associated ZIP7 phosphorylation (<xref rid="B130" ref-type="bibr">Tuncay et al., 2017</xref>).</p></sec><sec id="s4-2"><title>4.2 Metallothionein</title><p>Metallothionein (MT) is a low-molecular-weight protein rich in mercaptans, which functions as a scavenger of free radicals (<xref rid="B134" ref-type="bibr">Wang et al., 2001</xref>), It contains a high concentration of cysteine, which effectively protects cells and tissues from oxidative damage (<xref rid="B72" ref-type="bibr">Kang, 1999</xref>). There are four subtypes of MT: MT-I and MT-II are present in all tissues and organs of mammals, MT-III is unique to brain tissues, and MT-IV is found only in certain tissues containing lamellar squamous epithelial cells (<xref rid="B99" ref-type="bibr">Meloni et al., 2006</xref>). Cardio-specific overexpression of MT and catalase significantly inhibited acute (<xref rid="B73" ref-type="bibr">Kang et al., 1997</xref>) and chronic (<xref rid="B122" ref-type="bibr">Sun et al., 2001</xref>) cardiotoxicity induced by Dox, proved by characteristic histopathological, ultrastructural changes, and dysfunction. Cardiomyocyte apoptosis induced by Dox was significantly reduced in mice with cardiac-specific overexpression of MT (<xref rid="B74" ref-type="bibr">Kang et al., 2000</xref>). What&#8217;s more, Zinc-MT strongly inhibited lipid peroxidation when present during incubation (<xref rid="B127" ref-type="bibr">Thomas et al., 1986</xref>).</p></sec><sec id="s4-3"><title>4.3 Combining therapies for cardiac toxicity treatment</title><p>Researchers have made many attempts and innovations to reduce the cardiac side effects during chemotherapy. For example, Y. Zhang et al. found zinc-selenium tea can effectively alleviate the extent of myocardial fiber disarray, rupture, and inflammatory cell infiltration induced by nonylphenol (<xref rid="B151" ref-type="bibr">Zhang et al., 2023b</xref>); although green tea has a similar effect, not as pronounced as zinc-selenium tea (<xref rid="B151" ref-type="bibr">Zhang et al., 2023b</xref>). P.K. Badkoobeh found that the antioxidant nano-zinc oxide (nZnO) has a cellular protective effect for Dox-induced male gonadal toxicity (<xref rid="B12" ref-type="bibr">Badkoobeh et al., 2013</xref>). Zinc finger protein 260 (Zfp260), also known as phenylephrine-induced complex-1 (PEX1), is an effector of &#945;-1-adrenergic signaling in cardiac hypertrophy. It has been found that overexpression of Zfp260 can upregulate anti-apoptotic genes and reduce doxorubicin-induced apoptosis in primary cardiomyocyte (<xref rid="B92" ref-type="bibr">Li et al., 2022b</xref>). Researchers also evaluated the cardioprotective effects of zinc taurine solid dispersion in SD rats. After giving Dox treatment, zinc taurine was found to alleviate the decrease in blood pressure and left ventricular pressure caused by Dox (<xref rid="B139" ref-type="bibr">Wang et al., 2015</xref>). It also reduced serum Zn<sup>2+</sup> and albumin levels and inhibited cardiomyocyte apoptosis (<xref rid="B139" ref-type="bibr">Wang et al., 2015</xref>). In addition, R. Wu et al. found that Zn<sup>2+</sup>-Curcumin supplementation significantly attenuates Dox-induced zinc imbalance, improves Dox-induced cardiac dysfunction, reduces myocardial injury (<xref rid="B144" ref-type="bibr">Wu et al., 2019</xref>).</p></sec></sec><sec id="s5"><title>5 Maintenance of calcium homeostasis and promoting effect on DIC and potential therapeutic direction</title><p>Calcium is a vital trace element that plays various roles in the human body, both structurally and functionally. The concentration of intracellular and extracellular calcium is strictly regulated through processes such as intestinal absorption, renal reabsorption, and bone exchange, which are controlled by a group of interacting hormones, including parathyroid hormone, parathyroid hormone-related peptides, and key receptors (<xref rid="B98" ref-type="bibr">Matikainen et al., 2021</xref>), These mechanisms ensure that blood calcium concentrations and systemic calcium ion balance are maintained within a narrow range (<xref rid="B98" ref-type="bibr">Matikainen et al., 2021</xref>). Calcium exists in two forms in the body: as an inactive binding form and as the highly active bivalent cation Ca<sup>2+</sup>.</p><sec id="s5-1"><title>5.1 Calcium homeostasis</title><p>In cardiomyocyte, calcium is predominantly found in the SR. According to <xref rid="F4" ref-type="fig">Figure 4</xref>, under normal physiological conditions, the release of calcium ions from the SR generates ROS. However, under the influence of Dox, the release of Ca<sup>2+</sup> increases, leading to apoptosis of cardiomyocyte. On the other hand, chelating agents of Ca<sup>2+</sup> inhibit ROS production and cardiomyocyte apoptosis (<xref rid="B70" ref-type="bibr">Kalivendi et al., 2005</xref>). Disruption of Ca<sup>2+</sup> balance triggers activation of the ER stress response. Maintaining Ca<sup>2+</sup> homeostasis requires a highly integrated and complex system, which includes the plasma membrane Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCX), a system with low affinity but a strong capability to transport Ca<sup>2+</sup>. The plasma membrane Ca<sup>2+</sup> pump (PMCA) and the S(E)R calcium ATPase (SERCA) have a high affinity for Ca<sup>2+</sup> but poor capacity (<xref rid="B82" ref-type="bibr">Krebs et al., 2015</xref>). Similarly, in the case of DIC, ER stress can also induce cardiomyocyte apoptosis, further exacerbating the condition (<xref rid="B83" ref-type="bibr">Lakshmanan et al., 2013</xref>). Furthermore, during the metabolism of Dox, the toxic metabolite DOXOL is produced, which inhibits sodium/calcium exchange channels (<xref rid="B48" ref-type="bibr">Fu et al., 1990</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>Calcium depends on the transport of different proteins between cytoplasm and organelles, and calcium overload promotes apoptosis. Ca<sup>2+</sup> is pumped into the cytoplasm by L-Type channels and CaMKII. It then influences the calcium ion concentration in organelles such as mitochondria and endoplasmic reticulum through proteins like RyR, SERCA, and NCX. When there is calcium overload in cells, it results in endoplasmic reticulum stress and mitochondrial energy imbalance. This triggers the activation of apoptosis-related proteins, ultimately leading to myocardial disease. PMCA plasma membrane Ca<sup>2+</sup>-ATPases; CaMKII calcium/calmodulin-dependent protein kinase II; ATP adenosine triphosphate; SERCA sarcoendoplasmic reticulum calcium ATPase; RyR ryanodine receptor; NCX sodium (Na)-calcium exchanger; SR sarcoplasmic reticulum; mPTP mitochondrial permeability transition pore. Image from biorender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-14-1292088-g004.jpg"/></fig><p>In a rabbit model with DIC, Arai et al. found that reduced expression levels of the SR mRNA gene responsible for calcium transport are the main cause of disrupt calcium homeostasis (<xref rid="B9" ref-type="bibr">Arai et al., 1998</xref>). Therefore, several studies have identified targets related to ER stress, aiming to expand the possibilities for preventing and treating DIC. For instance, it has been observed that Stim1 expression is downregulated in Dox-treated mice cardiomyocyte. Conversely, cardio-specific deficiency of Stim1 worsens Dox-induced cardiac dysfunction and cardiomyocyte apoptosis, while cardio-specific overexpression of Stim1 alleviates these phenomenon (<xref rid="B154" ref-type="bibr">Zhu et al., 2021</xref>); Additionally, downregulation of Stim1 enhances Dox-induced ER stress in cardiomyocyte, whereas overexpression of Stim1 inhibits the activation of molecular markers of ER stress (<xref rid="B154" ref-type="bibr">Zhu et al., 2021</xref>).</p></sec><sec id="s5-2"><title>5.2 Calcium channel blockers</title><p>Dox also causes calcium overload in mitochondria. On one hand, Dox treatment can disrupt mitochondrial energy synthesis, and induce mutations and defects in mitochondrial DNA (<xref rid="B120" ref-type="bibr">Sheibani et al., 2022</xref>); On the other hand, elevated intracellular calcium concentration can also lead to mitochondrial dysfunction and apoptosis (<xref rid="B102" ref-type="bibr">Mitry and Edwards, 2016</xref>). To maintain the flow of Ca<sup>2+</sup> across the mitochondrial membrane, Ca<sup>2+</sup> enters the mitochondria through a specific non-adenosine triphosphate-dependent single transporter and then exits through Na<sup>+</sup> carriers or Ca<sup>2+</sup>/H<sup>+</sup> reverse transporters in the heart and liver, respectively (<xref rid="B104" ref-type="bibr">Mughal et al., 2018</xref>). Interestingly, calcium directly affects enzymes that stimulate the tricarboxylic acid cycle and the electron transport chain, resulting in increased oxidative phosphorylation (<xref rid="B64" ref-type="bibr">Ivannikov and Macleod, 2013</xref>). Mitochondria, in turn, regulate cellular calcium signaling by sequestering and buffering cytoplasmic calcium.</p><p>Calcium channel blockers can be used to prevent cellular death to alleviate calcium overload. Nicorandil, an indirect calcium channel blocker, can inhibit oxidative stress-induced apoptosis by opening mitochondrial KATP channels or activating NO/cGMP-dependent pathways (<xref rid="B106" ref-type="bibr">Nishikawa et al., 2006</xref>). Studies have shown that Nicorandil can preserve phosphocreatine and adenine nucleotide levels by restoring mitochondria&#8217;s oxidative phosphorylation ability and creatine kinase activity (<xref rid="B2" ref-type="bibr">Ahmed and El-Maraghy, 2013</xref>). Diltiazem (DIL), another calcium channel blocker, has been reported to downregulate the expression of the mitochondrial transporter ABCB1 gene in the human breast cancer cell line MCF-7 when used in combination with Dox. DIL treatment can reverse the resistance of breast cancer cells to Dox and has a protective effect against DIC (<xref rid="B4" ref-type="bibr">Al-Malky et al., 2019</xref>).</p></sec><sec id="s5-3"><title>5.3 Calcium sensitizer</title><p>There are three overall types of calcium sensitizer agents (<xref rid="B112" ref-type="bibr">Pollesello et al., 2016</xref>). Type I calcium sensitizers increase the affinity of Ca<sup>2+</sup> to troponin C either through direct action or conformational changes, enhancing myocardial contractility. Their mechanism of action is central, such as Pimobendan, CGP-48506, and Oxyphenamone. Type II calcium sensitizers act directly on cardiac myofilaments, promoting the regulation of actin and myosin, which increases the sensitivity of myocardial fibers to Ca<sup>2+</sup> but does not affect the affinity of troponin C to Ca<sup>2+</sup>. Their mechanism of action is downstream, such as Levosimendan (LEVO). Type III calcium sensitizer directly acts on the troponin C and is considered a downstream mechanism. Moreover, it exhibits myocontractile effects by activating the actomyosin ATPase, even in the absence of Ca<sup>2+</sup>, such as <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="EMD57033">EMD57033</ext-link>. While LEVO is one of the well-studied calcium sensitizer and vasodilator. Studies have shown that LEVO can activate the cAMP-PKA-PLN axis, reducing calcium overload in cardiomyocyte, and alleviating DIC (<xref rid="B36" ref-type="bibr">Efentakis et al., 2020</xref>). Additionally, LEVO can inhibit the activation of PTEN, promote the expression of P-Akt, decrease cell apoptosis, and repair cardiac function damage caused by Dox (<xref rid="B86" ref-type="bibr">Li et al., 2020a</xref>).</p></sec></sec><sec sec-type="discussion" id="s6"><title>6 Discussion</title><p>All of the metals mentioned above, although the amount needed by the human body is very small, can cause signs of disease when absent. Abnormal transport of metal ions has been observed in patients with cardiomyopathy caused by continuous use of Dox in cancer treatment and in rodents with cumulative dosing of Dox to model cardiomyopathy. Previous literature suggests that overload and deposition of endogenous metal ions are part of the mechanism of DIC. An effective metal chelator should have the ability to cross the BBB, be specific to a single metal ion, and not interfere with the normal physiological metabolism of metal ions (<xref rid="B136" ref-type="bibr">Wang et al., 2020b</xref>). At present, metal chelators that satisfy these three conditions have not yet been identified for clinical treatment of DIC. Ferroptosis currently has only one clinical treatment option, which is Dexrazoxane. Studies have shown that Ferrostatin 1 can inhibit ferroptosis more than Dexrazoxane in mice (<xref rid="B41" ref-type="bibr">Fang et al., 2019</xref>). Interestingly, researchers have pointed out that the <italic toggle="yes">in vivo</italic> therapeutic function of Ferrostatin 1 is weaker than <italic toggle="yes">in vitro</italic> due to its instability in plasma. To tackle this, a soluble Ferrostatin analog named UAMC-3203 has been developed. UAMC-3203 is a more stable and effective inhibitor of ferroptosis (<xref rid="B67" ref-type="bibr">Jin et al., 2022a</xref>).</p><p>Currently, we have discovered various chemical drugs, natural compounds or traditional Chinese medicine formulations that exhibit different mechanisms in combating DIC. Examples of chemical compounds include empagliflozin (<xref rid="B114" ref-type="bibr">Quagliariello et al., 2021</xref>), sulforaphane (<xref rid="B137" ref-type="bibr">Wang et al., 2022b</xref>), dexmedetomidine (<xref rid="B141" ref-type="bibr">Wang et al., 2022d</xref>). Natural products such as puerarin (<xref rid="B60" ref-type="bibr">Huang et al., 2022</xref>), isoquercitrin (<xref rid="B95" ref-type="bibr">Luo et al., 2023</xref>), icariside II (<xref rid="B51" ref-type="bibr">Gao et al., 2023</xref>) have also shown efficacy. Additionally, traditional Chinese medicine compound formulations like qing-xin-jie-yu granule (<xref rid="B150" ref-type="bibr">Zhang et al., 2023a</xref>), kaixin san (<xref rid="B19" ref-type="bibr">Cao et al., 2023</xref>), and qishenyiqi drops (<xref rid="B143" ref-type="bibr">Wu et al., 2023</xref>) have demonstrated the ability to inhibit ferroptosis and maintain intracellular iron balance. Furthermore, supplementation with Ginkgolide B (<xref rid="B50" ref-type="bibr">Gao et al., 2016</xref>), vitamins B and D (<xref rid="B10" ref-type="bibr">Awad et al., 2021</xref>), Epalastat analogue NARI-29 (<xref rid="B124" ref-type="bibr">Syamprasad et al., 2023</xref>), and d-Limonene complexed with cyclodextrin (<xref rid="B35" ref-type="bibr">Dur&#231;o et al., 2023</xref>) have been found to alleviate DIC through calcium-related pathways. Taurine zinc solid dispersions (<xref rid="B139" ref-type="bibr">Wang et al., 2015</xref>), Zn(ii)-curcumin supplementation (<xref rid="B144" ref-type="bibr">Wu et al., 2019</xref>), magnolol and honokiol complex (<xref rid="B3" ref-type="bibr">Aktay et al., 2023</xref>) have been shown to improve the abnormal state of Zn2+ during DIC. Interestingly, cannabidiol has the ability to restore normal calcium and zinc levels simultaneously, thereby playing a protective role for the heart (<xref rid="B46" ref-type="bibr">Fouad et al., 2013</xref>).</p><p>In addition to reducing DIC, metal ion overload also has certain cardiotoxic effects. For example, a series of previous meta-analysis studies conducted by Wang&#8217;s team found that an increase in dietary heme iron intake by 1&#160;mg per day led to a 7% increase in the risk of heart disease (<xref rid="B40" ref-type="bibr">Fang et al., 2015</xref>). Furthermore, hereditary hemochromatosis, an autosomal recessive genetic disease characterized by large deposits of Fe<sup>3+</sup> in multiple organs. According to a study by the Mayo Clinic in the United States, approximately one-third of hemochromatosis patients die from heart disease (<xref rid="B108" ref-type="bibr">Olson et al., 1987</xref>). Moreover, women with hemochromatosis have a lower risk of cardiovascular events than men, possibly due to persistent iron deficiency during women&#8217;s periods (<xref rid="B49" ref-type="bibr">Gaenzer et al., 2002</xref>). Similarly, uncombined or free copper is toxic, as almost all copper in the human body must be combined with copper proteins. Acute copper poisoning can lead to abdominal pain, nausea and vomiting, liver necrosis, kidney damage, and more. In terms of the cardiovascular system, it can lead to atherosclerosis. Excessive zinc or calcium in adults can also increase the risk of coronary heart disease and arteriosclerosis. As summarized in <xref rid="T1" ref-type="table">Table 1</xref>, Dox promotes apoptosis and mortality rates, induces myocardial diseases. However, when administered with metal ion inhibitors through various mechanisms, it exhibits significant cardiac protective effects. Metal ions have characteristics of a &#8220;double-edged sword,&#8221; so it is important to avoid excessive adjustment of their concentration.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Potential therapeutic interventions in Dox-induced cardiotoxicity <italic toggle="yes">in vivo/vitro</italic>.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">Metal ion species</th><th align="left" rowspan="1" colspan="1">Study model</th><th align="left" rowspan="1" colspan="1">Doxorubicin dosage and route of administration</th><th align="left" rowspan="1" colspan="1">Therapeutic intervention</th><th align="left" rowspan="1" colspan="1">Outcomes of therapy</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td rowspan="37" align="left" colspan="1">Iron</td><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/Ripk3<sup>&#8722;/&#8722;</sup> mice or wild-type mice</td><td rowspan="3" align="left" colspan="1">20&#160;mg/kg, ip, single dose</td><td rowspan="3" align="left" colspan="1">Ferrostatin 1 (1&#160;mg/kg, ip)</td><td align="left" rowspan="1" colspan="1">&#8595; Dox-induced cell mortality</td><td rowspan="3" align="left" colspan="1">
<xref rid="B41" ref-type="bibr">Fang et al. (2019)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Anp, Bnp and Myh7 mRNA levels</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; LVEF, LVFS</td></tr><tr><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/C75BL/6 mice</td><td rowspan="3" align="left" colspan="1">10&#160;mg/kg, ip, single dose</td><td rowspan="3" align="left" colspan="1">ZnPP (10&#160;mg/kg, ip)</td><td align="left" rowspan="1" colspan="1">&#8595; Ptgs2</td><td rowspan="3" align="left" colspan="1">
<xref rid="B41" ref-type="bibr">Fang et al. (2019)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; MDA</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Anp, Bnp and Myh7 mRNA levels</td></tr><tr><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/Sprague-Dawley rats</td><td rowspan="3" align="left" colspan="1">6&#160;mg/kg, iv, single dose</td><td rowspan="3" align="left" colspan="1">Feed iron-rich chow</td><td align="left" rowspan="1" colspan="1">&#8593; weight loss</td><td rowspan="3" align="left" colspan="1">
<xref rid="B109" ref-type="bibr">Panjrath et al. (2007)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; annexin uptake</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; Cardiomyocyte damage</td></tr><tr><td rowspan="5" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/C57BL/6 mice and neonatal Sprague Dawley rats, and <italic toggle="yes">in vitro</italic>/H9c2 cardiac cells</td><td rowspan="5" align="left" colspan="1">1&#160;&#956;M, 24&#160;h 2.5&#160;mg/kg, ip, 2 times per week for 3&#160;weeks</td><td rowspan="5" align="left" colspan="1">Epigallocatechin-3-gallate (20&#160;mg/kg/d, ig, for six consecutive weeks)</td><td align="left" rowspan="1" colspan="1">&#8595; CK-MB, LDH</td><td rowspan="5" align="left" colspan="1">
<xref rid="B56" ref-type="bibr">He et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; LVEF, LVFS</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; LC3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; P62</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; AMPK&#945;2</td></tr><tr><td rowspan="4" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/Hfe<sup>&#8722;/&#8722;</sup>mice or wild-type Hfe mice, and <italic toggle="yes">in vitro</italic>/H9c2 rat cardiomyocyte</td><td rowspan="4" align="left" colspan="1">10&#160;&#956;M, 24&#160;h 20&#160;mg/kg, ip, single dose</td><td rowspan="4" align="left" colspan="1">ABCB8 overexpression</td><td align="left" rowspan="1" colspan="1">&#8593; ABCB8</td><td rowspan="4" align="left" colspan="1">
<xref rid="B101" ref-type="bibr">Menon and Kim (2022)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Dox retention</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; mitochondrial iron</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; oxidative stress</td></tr><tr><td rowspan="5" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/Sprague-Dawley rats</td><td rowspan="5" align="left" colspan="1">15&#160;mg/kg, ip, single dose</td><td rowspan="5" align="left" colspan="1">Deferiprone (10&#160;mg/kg for 10&#160;days, po, once daily for 10&#160;days)</td><td align="left" rowspan="1" colspan="1">&#8595; Heart rate</td><td rowspan="5" align="left" colspan="1">
<xref rid="B37" ref-type="bibr">El-Ammar el et al. (2011)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; ST segment</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; CK-MD</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; LDH, MDA</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; GSH, SOD</td></tr><tr><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/Sprague-Dawley rats</td><td rowspan="3" align="left" colspan="1">2&#160;mg/kg/d, ip, for a week</td><td rowspan="3" align="left" colspan="1">D-&#945;-tocopherol succinate (2&#160;g/kg, po, for a week)</td><td align="left" rowspan="1" colspan="1">&#8595; Weight gain</td><td rowspan="3" align="left" colspan="1">
<xref rid="B15" ref-type="bibr">Berthiaume et al. (2005)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Heart weight</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; the content of tocopherols</td></tr><tr><td rowspan="5" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/TRIM21<sup>&#8722;/&#8722;</sup> or TRIM21<sup>+/+</sup> C57BL/6J mice and <italic toggle="yes">in vitro</italic>/mice embryonic fibroblasts and H9c cardiomyocyte line</td><td rowspan="5" align="left" colspan="1">20&#160;mg/kg, ip, single dose</td><td rowspan="5" align="left" colspan="1">Loss of TRIM21</td><td align="left" rowspan="1" colspan="1">&#8593; Survival time</td><td rowspan="5" align="left" colspan="1">
<xref rid="B57" ref-type="bibr">Hou et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; Cardiac function</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; 4-HNE</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; MDA</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Ferroptosis</td></tr><tr><td rowspan="6" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/Wistar albino rats</td><td rowspan="6" align="left" colspan="1">15&#160;mg/kg, ip, single dose</td><td rowspan="6" align="left" colspan="1">Hemin (2.5, 5, 10&#160;mg/kg/d, ip, for a week)</td><td align="left" rowspan="1" colspan="1">&#8595; CK-MB, LDH, MDA</td><td rowspan="6" align="left" colspan="1">
<xref rid="B116" ref-type="bibr">Refaie et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; GSH</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; Nrf-2, and HO-1 mRNA level</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; NF-&#954;B</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Cleaved caspase-3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; cardiac muscle fibers</td></tr><tr><td rowspan="3" align="left" colspan="1">Copper</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">In vivo</italic>/Sprague-Dawley rats</td><td align="left" rowspan="1" colspan="1">1, 2, or 4&#160;mg/kg, 1 time/week for 4&#160;weeks</td><td align="left" rowspan="1" colspan="1">Copper deficiency</td><td align="left" rowspan="1" colspan="1">&#8593; the activity of Cu, Zn superoxide dismutase, and glutathione S-transferase</td><td align="left" rowspan="1" colspan="1">
<xref rid="B42" ref-type="bibr">Fischer et al. (1992)</xref>
</td></tr><tr><td rowspan="2" align="left" colspan="1">
<italic toggle="yes">In vitro</italic>/HL/60 and its H<sub>2</sub>O<sub>2</sub>-resistant HP100 cells</td><td rowspan="2" align="left" colspan="1">1, 2, 5&#160;&#956;M, 3&#160;h</td><td rowspan="2" align="left" colspan="1">H<sub>2</sub>O<sub>2</sub>-resistant</td><td align="left" rowspan="1" colspan="1">&#8593; 8-oxodG</td><td rowspan="2" align="left" colspan="1">
<xref rid="B103" ref-type="bibr">Mizutani et al. (2003)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; DNA damage</td></tr><tr><td rowspan="26" align="left" colspan="1">Zinc</td><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vitro</italic>/ATCC CRL1446 and H9c2 cardiomyocyte</td><td rowspan="3" align="left" colspan="1">1&#160;&#956;M for 24&#160;h</td><td rowspan="3" align="left" colspan="1">PKC inhibitor</td><td align="left" rowspan="1" colspan="1">&#8593; intracellular-free Zn<sup>2+</sup>
</td><td rowspan="3" align="left" colspan="1">
<xref rid="B107" ref-type="bibr">Olgar et al. (2018)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; PUMA protein levels</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; ER</td></tr><tr><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/cardiac MT-overexpressing transgenic mice or normal controls</td><td rowspan="3" align="left" colspan="1">20&#160;mg/kg, ip, single dose</td><td rowspan="3" align="left" colspan="1">Metallothionein overexpression</td><td align="left" rowspan="1" colspan="1">Maintain the normal morphology of cardiomyocyte</td><td rowspan="3" align="left" colspan="1">
<xref rid="B73" ref-type="bibr">Kang et al. (1997)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; serum CPK activity</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; inotropy (left atrium)</td></tr><tr><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/cardiac-specific overexpression of MT transgenic mice or nontransgenic controls</td><td rowspan="3" align="left" colspan="1">4&#160;mg/kg, ip, 10 times in 7&#160;weeks</td><td rowspan="3" align="left" colspan="1">Metallothionein overexpression</td><td align="left" rowspan="1" colspan="1">&#8595; Cardiac hypertrophy</td><td rowspan="3" align="left" colspan="1">
<xref rid="B122" ref-type="bibr">Sun et al. (2001)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Dox-induced myocardial injury</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; The degree of cytoplasmic vacuolation retains the fine ultrastructure of mitochondria</td></tr><tr><td rowspan="2" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/cardiac-specific MT-overexpressing transgenic positive and negative FVB mice and <italic toggle="yes">in vitro</italic>/neonatal mice primary cardiomyocyte</td><td rowspan="2" align="left" colspan="1">15&#160;mg/kg, ip, single dose 0.1, 0.5, 1.0 mM, 6&#160;h</td><td rowspan="2" align="left" colspan="1">Metallothionein overexpression</td><td align="left" rowspan="1" colspan="1">&#8593; TUNEL-positive myocardium</td><td rowspan="2" align="left" colspan="1">
<xref rid="B74" ref-type="bibr">Kang et al. (2000)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; Morphological changes</td></tr><tr><td rowspan="5" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/Adult male Wistar rats</td><td rowspan="5" align="left" colspan="1">6&#160;mg/kg, ip, 3&#160;d</td><td rowspan="5" align="left" colspan="1">Co-administration of nano-zinc oxide (5&#160;mg/kg/d, 3&#160;d)</td><td align="left" rowspan="1" colspan="1">&#8595; plasma total antioxidant power</td><td rowspan="5" align="left" colspan="1">
<xref rid="B12" ref-type="bibr">Badkoobeh et al. (2013)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Lipid peroxidation</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; plasma testosterone</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; LH, Sperm count</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; DNA damage</td></tr><tr><td rowspan="6" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/Mature adult male Wistar rats</td><td rowspan="6" align="left" colspan="1">6&#160;mg/kg, ip, 3 times weekly for 8&#160;weeks</td><td rowspan="6" align="left" colspan="1">Co-administration of nano-zinc oxide (3&#160;mg/kg/d, 5 times weekly for 8&#160;weeks, po)</td><td align="left" rowspan="1" colspan="1">&#8595; GSH</td><td rowspan="6" align="left" colspan="1">
<xref rid="B38" ref-type="bibr">El-Maddawy and Abd El Naby (2019)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; CAT</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; MDA</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; reproductive organs</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; epididymal sperm count</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; live sperm</td></tr><tr><td rowspan="4" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/C57BL/6 mice and <italic toggle="yes">in votro</italic>/Primary rat cardiomyocyte</td><td rowspan="4" align="left" colspan="1">15&#160;mg/kg, ip, single dose 300&#160;nM</td><td rowspan="4" align="left" colspan="1">Phenylephrine-induced complex-1 overexpression</td><td align="left" rowspan="1" colspan="1">&#8593; Cytoplasmic vacuolization and myofibril loss</td><td rowspan="4" align="left" colspan="1">
<xref rid="B92" ref-type="bibr">Li et al. (2022b)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; The transcript and protein levels of GATA-4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Cell viability</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; Apoptosis</td></tr><tr><td rowspan="3" align="left" colspan="1">Calcium</td><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/cardiomyocyte-specific stim1 knockout or WT C57BL/6 mice and <italic toggle="yes">in vitro</italic>/AC16 cardiomyocyte</td><td rowspan="3" align="left" colspan="1">200&#160;&#956;L, 15&#160;mg/kg, at a rate of 0.5&#160;&#956;L/h, over a period of 14&#160;days</td><td rowspan="3" align="left" colspan="1">STIM1 overexpression</td><td align="left" rowspan="1" colspan="1">&#8595; AC16 cardiomyocyte apoptosis</td><td rowspan="3" align="left" colspan="1">
<xref rid="B154" ref-type="bibr">Zhu et al. (2021)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; Cardiac function</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; ER stress</td></tr><tr><td rowspan="26" align="left" colspan="1"/><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vitro</italic>/adult rat cardiomyocyte</td><td rowspan="3" align="left" colspan="1">3&#160;&#181;M</td><td align="left" rowspan="1" colspan="1">Ryanodine (20&#160;&#181;M)</td><td align="left" rowspan="1" colspan="1">&#8595; Dox-mediated SR Ca<sup>2+</sup> release</td><td rowspan="3" align="left" colspan="1">
<xref rid="B76" ref-type="bibr">Kim et al. (2006)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Dantrolene (2&#160;&#181;M)</td><td align="left" rowspan="1" colspan="1">&#8595; ROS generation</td></tr><tr><td align="left" rowspan="1" colspan="1">&#945;-lipoic acid (100&#160;&#181;M)</td><td align="left" rowspan="1" colspan="1">&#8595; Caspase 3 activity</td></tr><tr><td rowspan="4" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/Wistar rats</td><td rowspan="4" align="left" colspan="1">3&#160;mg/kg, ip, 3 times weekly(every other day), for a cumulative dose of 18&#160;mg/kg</td><td rowspan="4" align="left" colspan="1">Nicorandil (3&#160;mg/kg, po, over a period of 2&#160;weeks)</td><td align="left" rowspan="1" colspan="1">&#8595; Rats mortality</td><td rowspan="4" align="left" colspan="1">
<xref rid="B2" ref-type="bibr">Ahmed and El-Maraghy (2013)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; Heart rate</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Oxidative stress, apoptosis</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; the mitochondrial overall injury score</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">In vivo</italic>
<italic toggle="yes">/</italic>Wistar rats</td><td align="left" rowspan="1" colspan="1">15&#160;mg/kg, ip, single dose</td><td align="left" rowspan="1" colspan="1">Diltiazem (4&#160;mg/kg, ip, single dose)</td><td align="left" rowspan="1" colspan="1">&#8595; ABCB1 mRNA level</td><td rowspan="4" align="left" colspan="1">
<xref rid="B4" ref-type="bibr">Al-Malky et al. (2019)</xref>
</td></tr><tr><td rowspan="3" align="left" colspan="1">
<italic toggle="yes">In vitro</italic>/human breast cancer cell line MCF-7</td><td rowspan="3" align="left" colspan="1">0.25 or 1&#160;&#956;g/mL, 48&#160;h</td><td rowspan="3" align="left" colspan="1">Diltiazem (20&#160;&#956;g/mL, 48&#160;h)</td><td align="left" rowspan="1" colspan="1">&#8593; FOXO3a, P53</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; CK-MB, MDA</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; TAC, GPx</td></tr><tr><td align="left" rowspan="1" colspan="1">Protocol 1: <italic toggle="yes">In vivo</italic>/Wistar rats</td><td align="left" rowspan="1" colspan="1">Protocol 1: 20&#160;mg/kg, ip, single dose</td><td align="left" rowspan="1" colspan="1">Protocol 1: Levosimendan (12 or 24&#160;&#956;g/kg, ip, single dose)</td><td align="left" rowspan="1" colspan="1">&#8593; Myocardial contractility</td><td rowspan="8" align="left" colspan="1">
<xref rid="B36" ref-type="bibr">Efentakis et al. (2020)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Protocol 2: <italic toggle="yes">In vivo</italic>/PLN<sup>&#8722;/&#8722;</sup> or normal SV129 mice</td><td align="left" rowspan="1" colspan="1">Protocol 2: 3&#160;mg/kg, ip, 3 times weekly</td><td align="left" rowspan="1" colspan="1">Protocol 2: Levosimendan (24&#160;&#956;g/kg, ip, single dose)</td><td align="left" rowspan="1" colspan="1">&#8595; Myocardial fibrosis</td></tr><tr><td rowspan="6" align="left" colspan="1">Protocol 3: <italic toggle="yes">In vivo</italic>/C57BL/6 mice</td><td rowspan="6" align="left" colspan="1">Protocol 3: 3&#160;mg/kg, ip, 3 times weekly</td><td rowspan="6" align="left" colspan="1">Protocol 3: Levosimendan (6&#160;&#956;g/kg, ip, for 4 times or 24&#160;&#956;g/kg, ip, single dose)</td><td align="left" rowspan="1" colspan="1">&#8595; Cardiac hypertrophy</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; MDA</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; ROS accumulation</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Dox-induced changes of iNOs and MnSOD</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; Phosphorylation of eNOs and Akt</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; cGMP</td></tr><tr><td rowspan="7" align="left" colspan="1">
<italic toggle="yes">In vivo</italic>/C57L/6 mice and <italic toggle="yes">in vitro</italic>/H9c2 cells</td><td rowspan="7" align="left" colspan="1">5&#160;mg/kg, ip, 1 time/week for 4&#160;weeks 1&#160;&#956;mol/mL, 24&#160;h</td><td rowspan="7" align="left" colspan="1">Levosimendan (1&#160;mg/kg, po, once daily for 4&#160;weeks) Levosimendan (10&#160;&#956;mol/mL, 2&#160;h)</td><td align="left" rowspan="1" colspan="1">&#8593; LVEF, LVFS</td><td rowspan="7" align="left" colspan="1">
<xref rid="B86" ref-type="bibr">Li et al. (2020a)</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Cardiac dysfunction</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; HW/TL</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Anp, Bnp mRNA levels</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; BAX, c-caspase-3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8593; Bcl-2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8595; Apoptosis</td></tr></tbody></table></table-wrap><p>Despite its side and adverse effects, Dox remains a key drug in many cancer treatments. The mechanism of DIC is influenced by many factors. Depending on the mechanism, different strategies can be developed to prevent or reduce the adverse cardiotoxicity of Dox. Previous studies have shown that ADAR2 overexpression attenuates DIC by enhancing cardiac function and reducing apoptosis (<xref rid="B145" ref-type="bibr">Wu et al., 2022</xref>). Similarly, DIC can be alleviated by activating some classical signaling pathways such as cAMP/PKA/SIRT1 (<xref rid="B61" ref-type="bibr">Hu et al., 2020</xref>), or AKT/SIRT3/SOD2 (<xref rid="B91" ref-type="bibr">Liu et al., 2022</xref>). Recently, some potential DIC therapeutic targets have been newly discovered, such as PDE10A (<xref rid="B27" ref-type="bibr">Chen et al., 2023</xref>), Sestrin 2 (<xref rid="B133" ref-type="bibr">Wang et al., 2022a</xref>), FAM134B (<xref rid="B115" ref-type="bibr">Qu et al., 2022</xref>), TFEB (<xref rid="B25" ref-type="bibr">Chen et al., 2022</xref>), etc., which play a cardioprotective role in reducing apoptosis, improving cardiac function, reducing oxidative stress and endoplasmic reticulum stress, and promoting autophagy. In addition, some non-coding RNAs have been shown to play important roles in DIC, such as miR-128-3p (<xref rid="B153" ref-type="bibr">Zhao et al., 2019</xref>), miR-451 (<xref rid="B88" ref-type="bibr">Li et al., 2019</xref>), miR-152 (<xref rid="B149" ref-type="bibr">Zhang et al., 2021</xref>), miR-125b (<xref rid="B68" ref-type="bibr">Jin et al., 2022b</xref>), etc. Recently, there are also newly discovered drugs with evidence of reducing DIC, such as Di&#8217;ao Xinxuekang capsule (<xref rid="B93" ref-type="bibr">Li et al., 2022c</xref>), tanshinone I (<xref rid="B65" ref-type="bibr">Jiang et al., 2022</xref>), glycyrrhetinic acid (<xref rid="B26" ref-type="bibr">Cheng et al., 2022</xref>), and Berberine (<xref rid="B138" ref-type="bibr">Wang et al., 2023</xref>), etc.</p><p>This paper discusses various metal ion chelators, ionic carriers, metal complexes, and natural chemical products that can reduce ROS production by regulating endogenous metal ion homeostasis, reducing oxidative stress and mitochondrial dysfunction, and thereby alleviating the cardiac toxicity of Dox. In future studies, it is hoped that by further improving the structure and deficiencies of these drugs, they will not only be effective at the animal and cellular level, but can also be used clinically through drug clinical trials to prevent or treat DIC.</p></sec></body><back><sec id="s7"><title>Author contributions</title><p>NZ: Investigation, Visualization, Writing&#8211;original draft. SW: Investigation, Methodology, Writing&#8211;review and editing. TS: Resources, Writing&#8211;review and editing. SX: Supervision, Writing&#8211;review and editing. JL: Investigation, Writing&#8211;review and editing. WL: Conceptualization, Funding acquisition, Writing&#8211;review and editing. BZ: Funding acquisition, Writing&#8211;review and editing, Supervision.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ide</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tadokoro</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyamoto</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Furusawa</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis</article-title>. <source>Sci. Signal</source><volume>15</volume>, <fpage>eabn8017</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.abn8017</pub-id><pub-id pub-id-type="pmid">36318618</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>El-Maraghy</surname><given-names>S. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection</article-title>. <source>Biochem. Pharmacol.</source><volume>86</volume>, <fpage>1301</fpage>&#8211;<lpage>1310</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2013.07.005</pub-id><pub-id pub-id-type="pmid">23872193</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aktay</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bitirim</surname><given-names>C. V.</given-names></name><name name-style="western"><surname>Olgar</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Durak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tuncay</surname><given-names>E.</given-names></name><name name-style="western"><surname>Billur</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Cardioprotective role of a magnolol and honokiol complex in the prevention of doxorubicin-mediated cardiotoxicity in adult rats</article-title>. <source>Mol. Cell Biochem</source>. <pub-id pub-id-type="doi">10.1007/s11010-023-04728-w</pub-id><pub-id pub-id-type="pmid">37074505</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Malky</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Osman</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Damanhouri</surname><given-names>Z. A.</given-names></name><name name-style="western"><surname>Alkreathy</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Al Aama</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Ramadan</surname><given-names>W. S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against cardiotoxicity in experimental animals</article-title>. <source>Cancer Cell Int.</source><volume>19</volume>, <fpage>191</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-019-0912-0</pub-id><pub-id pub-id-type="pmid">31367189</pub-id><pub-id pub-id-type="pmcid">PMC6657176</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>M. E.</given-names></name></person-group> (<year>1998</year>). <article-title>Glutathione: an overview of biosynthesis and modulation</article-title>. <source>Chem. Biol. Interact.</source><volume>111-112</volume>, <fpage>1</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/s0009-2797(97)00146-4</pub-id><pub-id pub-id-type="pmid">9679538</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asenova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nedkova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kolevakolarova</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Copper in the human organism</article-title>. <source>Trakia J. Sci</source>.</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anjum</surname><given-names>R.</given-names></name><name name-style="western"><surname>Palanimuthu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kalinowski</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Kovacevic</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Synthesis, characterization, and <italic toggle="yes">in vitro</italic> anticancer activity of copper and zinc bis(thiosemicarbazone) complexes</article-title>. <source>Inorg. Chem.</source><volume>58</volume>, <fpage>13709</fpage>&#8211;<lpage>13723</lpage>. <pub-id pub-id-type="doi">10.1021/acs.inorgchem.9b01281</pub-id><pub-id pub-id-type="pmid">31339305</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apresova</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Efremova</surname><given-names>I. E.</given-names></name><name name-style="western"><surname>Babayants</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Cheknev</surname><given-names>S. B.</given-names></name></person-group> (<year>2014</year>). <article-title>&#947;-Globulin fraction proteins and their metal complexes with copper cations in induction of IL-8 production</article-title>. <source>Bull. Exp. Biol. Med.</source><volume>156</volume>, <fpage>823</fpage>&#8211;<lpage>825</lpage>. <pub-id pub-id-type="doi">10.1007/s10517-014-2460-x</pub-id><pub-id pub-id-type="pmid">24824707</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tomaru</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takizawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sekiguchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits</article-title>. <source>J. Mol. Cell Cardiol.</source><volume>30</volume>, <fpage>243</fpage>&#8211;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1006/jmcc.1997.0588</pub-id><pub-id pub-id-type="pmid">9515001</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awad</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>El-Derany</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Mantawy</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Michel</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>El-Naa</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Salah El-Din</surname><given-names>R. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Comparative study on beneficial effects of vitamins B and D in attenuating doxorubicin induced cardiotoxicity in rats: emphasis on calcium homeostasis</article-title>. <source>Biomed. Pharmacother.</source><volume>140</volume>, <fpage>111679</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111679</pub-id><pub-id pub-id-type="pmid">34029952</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baba</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Higa</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Horiuchi</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Suhara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source><volume>314</volume>, <fpage>H659</fpage>&#8211;<lpage>H668</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00452.2017</pub-id><pub-id pub-id-type="pmid">29127238</pub-id><pub-id pub-id-type="pmcid">PMC5899260</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badkoobeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Parivar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Badkoobeh</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Kalantar</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Salabat</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Effect of nano-zinc oxide on doxorubicin-induced oxidative stress and sperm disorders in adult male Wistar rats</article-title>. <source>Iran. J. Reproductive Med.</source><volume>11</volume>, <fpage>355</fpage>&#8211;<lpage>364</lpage>.<pub-id pub-id-type="pmcid">PMC3941413</pub-id><pub-id pub-id-type="pmid">24639766</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>I.</given-names></name></person-group> (<year>2013</year>). <article-title>Metallomics and the cell: some definitions and general comments</article-title>. <source>Met. Ions Life Sci.</source><volume>12</volume>, <fpage>1</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1007/978-94-007-5561-1_1</pub-id><pub-id pub-id-type="pmid">23595668</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bay&#305;R</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kara</surname><given-names>H.</given-names></name><name name-style="western"><surname>K&#305;Y&#305;C&#305;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ozt&#252;RK</surname><given-names>B.</given-names></name><name name-style="western"><surname>Aky&#252;REK</surname><given-names>F.</given-names></name></person-group> (<year>2013</year>). <article-title>Levels of selenium, zinc, copper, and cardiac troponin I in serum of patients with acute coronary syndrome</article-title>. <source>Biol. Trace Elem. Res.</source><volume>154</volume>, <fpage>352</fpage>&#8211;<lpage>356</lpage>. <pub-id pub-id-type="doi">10.1007/s12011-013-9754-0</pub-id><pub-id pub-id-type="pmid">23904327</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berthiaume</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Fariss</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>K. B.</given-names></name></person-group> (<year>2005</year>). <article-title>Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction</article-title>. <source>Cardiovasc Toxicol.</source><volume>5</volume>, <fpage>257</fpage>&#8211;<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1385/ct:5:3:257</pub-id><pub-id pub-id-type="pmid">16244371</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhuvanasundar</surname><given-names>R.</given-names></name><name name-style="western"><surname>John</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sulochana</surname><given-names>K. N.</given-names></name><name name-style="western"><surname>Coral</surname><given-names>K.</given-names></name><name name-style="western"><surname>Deepa</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Umashankar</surname><given-names>V.</given-names></name></person-group> (<year>2014</year>). <article-title>A molecular model of human Lysyl Oxidase (LOX) with optimal copper orientation in the catalytic cavity for induced fit docking studies with potential modulators</article-title>. <source>Bioinformation</source><volume>10</volume>, <fpage>406</fpage>&#8211;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.6026/97320630010406</pub-id><pub-id pub-id-type="pmid">25187679</pub-id><pub-id pub-id-type="pmcid">PMC4135287</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsanaclis</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Zagzag</surname><given-names>D.</given-names></name></person-group> (<year>1990</year>). <article-title>Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain</article-title>. <source>Neurosurgery</source><volume>26</volume>, <fpage>391</fpage>&#8211;<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1097/00006123-199003000-00003</pub-id><pub-id pub-id-type="pmid">2320207</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brewer</surname><given-names>G. J.</given-names></name></person-group> (<year>2009</year>). <article-title>The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer's disease</article-title>. <source>J. Am. Coll. Nutr.</source><volume>28</volume>, <fpage>238</fpage>&#8211;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1080/07315724.2009.10719777</pub-id><pub-id pub-id-type="pmid">20150596</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Chinese traditional formula Kaixin San suppressed ferroptosis of hippocampal neurons and cardiomyocytes in mice with paradoxical sleep deprivation</article-title>. <source>J. Ethnopharmacol.</source><volume>304</volume>, <fpage>116034</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2022.116034</pub-id><pub-id pub-id-type="pmid">36529245</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cater</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): therapeutic indication for prostate cancer</article-title>. <source>Biochem. J.</source><volume>436</volume>, <fpage>481</fpage>&#8211;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20110123</pub-id><pub-id pub-id-type="pmid">21426304</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cater</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Wolyniec</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klaver</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bilandzic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>B. M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Increasing intracellular bioavailable copper selectively targets prostate cancer cells</article-title>. <source>ACS Chem. Biol.</source><volume>8</volume>, <fpage>1621</fpage>&#8211;<lpage>1631</lpage>. <pub-id pub-id-type="doi">10.1021/cb400198p</pub-id><pub-id pub-id-type="pmid">23656859</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Reduction in mitochondrial iron alleviates cardiac damage during injury</article-title>. <source>EMBO Mol. Med.</source><volume>8</volume>, <fpage>247</fpage>&#8211;<lpage>267</lpage>. <pub-id pub-id-type="doi">10.15252/emmm.201505748</pub-id><pub-id pub-id-type="pmid">26896449</pub-id><pub-id pub-id-type="pmcid">PMC4772952</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arjmand</surname><given-names>F.</given-names></name></person-group> (<year>2007</year>). <article-title>DNA binding studies of novel Copper(II) complexes containing L-tryptophan as chiral auxiliary: <italic toggle="yes">in vitro</italic> antitumor activity of Cu-Sn2 complex in human neuroblastoma cells</article-title>. <source>Inorg. Chem.</source><volume>46</volume>, <fpage>3072</fpage>&#8211;<lpage>3082</lpage>. <pub-id pub-id-type="doi">10.1021/ic061753a</pub-id><pub-id pub-id-type="pmid">17378549</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Q. C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barrea</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts</article-title>. <source>Cancer Res.</source><volume>67</volume>, <fpage>1636</fpage>&#8211;<lpage>1644</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3546</pub-id><pub-id pub-id-type="pmid">17308104</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Que</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Elabela ameliorates doxorubicin-induced cardiotoxicity by promoting autophagic flux through TFEB pathway</article-title>. <source>Pharmacol. Res.</source><volume>178</volume>, <fpage>106186</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2022.106186</pub-id><pub-id pub-id-type="pmid">35306141</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Natural compound glycyrrhetinic acid protects against doxorubicin-induced cardiotoxicity by activating the Nrf2/HO-1 signaling pathway</article-title>. <source>Phytomedicine</source><volume>106</volume>, <fpage>154407</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2022.154407</pub-id><pub-id pub-id-type="pmid">36070662</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mickelsen</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>PDE10A inactivation prevents doxorubicin-induced cardiotoxicity and tumor growth</article-title>. <source>Circ. Res.</source><volume>133</volume>, <fpage>138</fpage>&#8211;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.322264</pub-id><pub-id pub-id-type="pmid">37232184</pub-id><pub-id pub-id-type="pmcid">PMC10428174</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>C.</given-names></name><name name-style="western"><surname>Teknos</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Barrios</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Dick</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Merajver</surname><given-names>S. D.</given-names></name></person-group> (<year>2001</year>). <article-title>The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma</article-title>. <source>Laryngoscope</source><volume>111</volume>, <fpage>696</fpage>&#8211;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1097/00005537-200104000-00024</pub-id><pub-id pub-id-type="pmid">11359142</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crowe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jackaman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beddoes</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Ricciardo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>D. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration</article-title>. <source>PLoS One</source><volume>8</volume>, <fpage>e73684</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0073684</pub-id><pub-id pub-id-type="pmid">24013775</pub-id><pub-id pub-id-type="pmcid">PMC3754934</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dabravolski</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Sadykhov</surname><given-names>N. K.</given-names></name><name name-style="western"><surname>Kartuesov</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Borisov</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Sukhorukov</surname><given-names>V. N.</given-names></name><name name-style="western"><surname>Orekhov</surname><given-names>A. N.</given-names></name></person-group> (<year>2022</year>). <article-title>Interplay between Zn(2+) homeostasis and mitochondrial functions in cardiovascular diseases and heart ageing</article-title>. <source>Int. J. Mol. Sci.</source><volume>23</volume>, <fpage>6890</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23136890</pub-id><pub-id pub-id-type="pmid">35805904</pub-id><pub-id pub-id-type="pmcid">PMC9266371</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denoyer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Masaldan</surname><given-names>S.</given-names></name><name name-style="western"><surname>La Fontaine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cater</surname><given-names>M. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Targeting copper in cancer therapy: 'Copper that Cancer</article-title>. <source>Metallomics</source><volume>7</volume>, <fpage>1459</fpage>&#8211;<lpage>1476</lpage>. <pub-id pub-id-type="doi">10.1039/c5mt00149h</pub-id><pub-id pub-id-type="pmid">26313539</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dikalova</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Bikineyeva</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Budzyn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nazarewicz</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Mccann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Therapeutic targeting of mitochondrial superoxide in hypertension</article-title>. <source>Circ. Res.</source><volume>107</volume>, <fpage>106</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.214601</pub-id><pub-id pub-id-type="pmid">20448215</pub-id><pub-id pub-id-type="pmcid">PMC2901409</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinkova-Kostova</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Talalay</surname><given-names>P.</given-names></name></person-group> (<year>2008</year>). <article-title>Direct and indirect antioxidant properties of inducers of cytoprotective proteins</article-title>. <source>Mol. Nutr. Food Res.</source><volume>52</volume> (<issue>1</issue>), <fpage>S128</fpage>&#8211;<lpage>S138</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.200700195</pub-id><pub-id pub-id-type="pmid">18327872</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lessnick</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>W. C.</given-names></name><name name-style="western"><surname>Stockwell</surname><given-names>B. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells</article-title>. <source>Cancer Cell</source><volume>3</volume>, <fpage>285</fpage>&#8211;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/s1535-6108(03)00050-3</pub-id><pub-id pub-id-type="pmid">12676586</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dur&#231;O</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Rhana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>d-Limonene complexed with cyclodextrin attenuates cardiac arrhythmias in an experimental model of doxorubicin-induced cardiotoxicity: possible involvement of calcium/calmodulin-dependent protein kinase type II</article-title>. <source>Toxicol. Appl. Pharmacol.</source><volume>474</volume>, <fpage>116609</fpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2023.116609</pub-id><pub-id pub-id-type="pmid">37392997</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Efentakis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Varela</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chavdoula</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sigala</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sanoudou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tenta</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy</article-title>. <source>Cardiovasc Res.</source><volume>116</volume>, <fpage>576</fpage>&#8211;<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvz163</pub-id><pub-id pub-id-type="pmid">31228183</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Ammar</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Said</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Suddek</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>El-Damarawy</surname><given-names>S. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats</article-title>. <source>Can. J. Physiol. Pharmacol.</source><volume>89</volume>, <fpage>269</fpage>&#8211;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1139/y11-020</pub-id><pub-id pub-id-type="pmid">21526973</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Maddawy</surname><given-names>Z. K.</given-names></name><name name-style="western"><surname>Abd El Naby</surname><given-names>W. S. H.</given-names></name></person-group> (<year>2019</year>). <article-title>Protective effects of zinc oxide nanoparticles against doxorubicin induced testicular toxicity and DNA damage in male rats</article-title>. <source>Toxicol. Res. (Camb)</source><volume>8</volume>, <fpage>654</fpage>&#8211;<lpage>662</lpage>. <pub-id pub-id-type="doi">10.1039/c9tx00052f</pub-id><pub-id pub-id-type="pmid">31588342</pub-id><pub-id pub-id-type="pmcid">PMC6762007</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewer</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Lippman</surname><given-names>S. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity</article-title>. <source>J. Clin. Oncol.</source><volume>23</volume>, <fpage>2900</fpage>&#8211;<lpage>2902</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2005.05.827</pub-id><pub-id pub-id-type="pmid">15860848</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>An</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Dietary intake of heme iron and risk of cardiovascular disease: a dose-response meta-analysis of prospective cohort studies</article-title>. <source>Nutr. Metab. Cardiovasc Dis.</source><volume>25</volume>, <fpage>24</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.numecd.2014.09.002</pub-id><pub-id pub-id-type="pmid">25439662</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Ferroptosis as a target for protection against cardiomyopathy</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>116</volume>, <fpage>2672</fpage>&#8211;<lpage>2680</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1821022116</pub-id><pub-id pub-id-type="pmid">30692261</pub-id><pub-id pub-id-type="pmcid">PMC6377499</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Tackett</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Howerth</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M. A.</given-names></name></person-group> (<year>1992</year>). <article-title>Copper deficient rat heart can compensate for doxorubicin-induced oxidant stress</article-title>. <source>Biol. Trace Elem. Res.</source><volume>37</volume>, <fpage>233</fpage>&#8211;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1007/bf02783798</pub-id><pub-id pub-id-type="pmid">7688536</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Tackett</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Howerth</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M. A.</given-names></name></person-group> (<year>1993</year>). <article-title>Copper deficient rat heart can compensate for doxorubicin-induced oxidant stress</article-title>. <source>Biol. Trace Elem. Res.</source><volume>37</volume>, <fpage>233</fpage>&#8211;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1007/BF02783798</pub-id><pub-id pub-id-type="pmid">7688536</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Byers</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Shifrine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>A. S.</given-names></name></person-group> (<year>1976</year>). <article-title>Copper and zinc levels in serum from human patients with sarcomas</article-title>. <source>Cancer</source><volume>37</volume>, <fpage>356</fpage>&#8211;<lpage>363</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(197601)37:1&amp;#x0003c;356::aid-cncr2820370146&amp;#x0003e;3.0.co;2-w</pub-id><pub-id pub-id-type="pmid">764964</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forcina</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>S. J.</given-names></name></person-group> (<year>2019</year>). <article-title>GPX4 at the crossroads of lipid homeostasis and ferroptosis</article-title>. <source>Proteomics</source><volume>19</volume>, <fpage>e1800311</fpage>. <pub-id pub-id-type="doi">10.1002/pmic.201800311</pub-id><pub-id pub-id-type="pmid">30888116</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fouad</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Albuali</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Al-Mulhim</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Jresat</surname><given-names>I.</given-names></name></person-group> (<year>2013</year>). <article-title>Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity</article-title>. <source>Environ. Toxicol. Pharmacol.</source><volume>36</volume>, <fpage>347</fpage>&#8211;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1016/j.etap.2013.04.018</pub-id><pub-id pub-id-type="pmid">23721741</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedmann Angeli</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>M.</given-names></name><name name-style="western"><surname>Proneth</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tyurina</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Tyurin</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>V. J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice</article-title>. <source>Nat. Cell Biol.</source><volume>16</volume>, <fpage>1180</fpage>&#8211;<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.1038/ncb3064</pub-id><pub-id pub-id-type="pmid">25402683</pub-id><pub-id pub-id-type="pmcid">PMC4894846</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>L. X.</given-names></name><name name-style="western"><surname>Waagstein</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hjalmarson</surname><given-names>A.</given-names></name></person-group> (<year>1990</year>). <article-title>A new insight into adriamycin-induced cardiotoxicity</article-title>. <source>Int. J. Cardiol.</source><volume>29</volume>, <fpage>15</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/0167-5273(90)90267-9</pub-id><pub-id pub-id-type="pmid">2262210</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaenzer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marschang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sturm</surname><given-names>W.</given-names></name><name name-style="western"><surname>Neumayr</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>W.</given-names></name><name name-style="western"><surname>Patsch</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis</article-title>. <source>J. Am. Coll. Cardiol.</source><volume>40</volume>, <fpage>2189</fpage>&#8211;<lpage>2194</lpage>. <pub-id pub-id-type="doi">10.1016/s0735-1097(02)02611-6</pub-id><pub-id pub-id-type="pmid">12505233</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>Ginkgolide B exerts cardioprotective properties against doxorubicin-induced cardiotoxicity by regulating reactive oxygen species, Akt and calcium signaling pathways <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>
</article-title>. <source>PLoS One</source><volume>11</volume>, <fpage>e0168219</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0168219</pub-id><pub-id pub-id-type="pmid">27973574</pub-id><pub-id pub-id-type="pmcid">PMC5156426</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Icariside II preconditioning evokes robust neuroprotection against ischaemic stroke, by targeting Nrf2 and the OXPHOS/NF-&#954;B/ferroptosis pathway</article-title>. <source>Br. J. Pharmacol.</source><volume>180</volume>, <fpage>308</fpage>&#8211;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15961</pub-id><pub-id pub-id-type="pmid">36166825</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Enhanced expression of SLC4A11 by tert-Butylhydroquinone is mediated by direct binding of Nrf2 to the promoter of SLC4A11</article-title>. <source>Free Radic. Biol. Med.</source><volume>167</volume>, <fpage>299</fpage>&#8211;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.03.006</pub-id><pub-id pub-id-type="pmid">33744340</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mumper</surname><given-names>R. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Elevated copper and oxidative stress in cancer cells as a target for cancer treatment</article-title>. <source>Cancer Treat. Rev.</source><volume>35</volume>, <fpage>32</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctrv.2008.07.004</pub-id><pub-id pub-id-type="pmid">18774652</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutteridge</surname><given-names>J. M.</given-names></name></person-group> (<year>1984</year>). <article-title>Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex</article-title>. <source>Biochem. Pharmacol.</source><volume>33</volume>, <fpage>1725</fpage>&#8211;<lpage>1728</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(84)90340-x</pub-id><pub-id pub-id-type="pmid">6329216</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Terentyev</surname><given-names>D.</given-names></name></person-group> (<year>2019</year>). <article-title>Altered intracellular calcium homeostasis and arrhythmogenesis in the aged heart</article-title>. <source>Int. J. Mol. Sci.</source><volume>20</volume>, <fpage>2386</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20102386</pub-id><pub-id pub-id-type="pmid">31091723</pub-id><pub-id pub-id-type="pmcid">PMC6566636</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>D.</given-names></name><name name-style="western"><surname>He</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Epigallocatechin-3-gallate pretreatment alleviates doxorubicin-induced ferroptosis and cardiotoxicity by upregulating AMPK&#945;2 and activating adaptive autophagy</article-title>. <source>Redox Biol.</source><volume>48</volume>, <fpage>102185</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2021.102185</pub-id><pub-id pub-id-type="pmid">34775319</pub-id><pub-id pub-id-type="pmcid">PMC8600154</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin</article-title>. <source>EBioMedicine</source><volume>69</volume>, <fpage>103456</fpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103456</pub-id><pub-id pub-id-type="pmid">34233258</pub-id><pub-id pub-id-type="pmcid">PMC8261003</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X. L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X. S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X. Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Pathological concentration of zinc dramatically accelerates abnormal aggregation of full-length human Tau and thereby significantly increases Tau toxicity in neuronal cells</article-title>. <source>Biochim. Biophys. Acta Mol. Basis Dis.</source><volume>1863</volume>, <fpage>414</fpage>&#8211;<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2016.11.022</pub-id><pub-id pub-id-type="pmid">27890528</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kirschke</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y. Y.</given-names></name></person-group> (<year>2005</year>). <article-title>The ZIP7 gene (Slc39a7) encodes a zinc transporter involved in zinc homeostasis of the Golgi apparatus</article-title>. <source>J. Biol. Chem.</source><volume>280</volume>, <fpage>15456</fpage>&#8211;<lpage>15463</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M412188200</pub-id><pub-id pub-id-type="pmid">15705588</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Puerarin attenuates oxidative stress and ferroptosis via AMPK/PGC1&#945;/Nrf2 pathway after subarachnoid hemorrhage in rats</article-title>. <source>Antioxidants (Basel)</source><volume>11</volume>, <fpage>1259</fpage>. <pub-id pub-id-type="doi">10.3390/antiox11071259</pub-id><pub-id pub-id-type="pmid">35883750</pub-id><pub-id pub-id-type="pmcid">PMC9312059</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y. P.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway</article-title>. <source>Redox Biol.</source><volume>37</volume>, <fpage>101747</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2020.101747</pub-id><pub-id pub-id-type="pmid">33045622</pub-id><pub-id pub-id-type="pmcid">PMC7558217</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ghanefar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bayeva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khechaduri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naga Prasad</surname><given-names>S. V.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation</article-title>. <source>J. Clin. Invest.</source><volume>124</volume>, <fpage>617</fpage>&#8211;<lpage>630</lpage>. <pub-id pub-id-type="doi">10.1172/JCI72931</pub-id><pub-id pub-id-type="pmid">24382354</pub-id><pub-id pub-id-type="pmcid">PMC3904631</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andreux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Poitry-Yamate</surname><given-names>C.</given-names></name><name name-style="western"><surname>Auwerx</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>Bioavailable copper modulates oxidative phosphorylation and growth of tumors</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>110</volume>, <fpage>19507</fpage>&#8211;<lpage>19512</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1318431110</pub-id><pub-id pub-id-type="pmid">24218578</pub-id><pub-id pub-id-type="pmcid">PMC3845132</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivannikov</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Macleod</surname><given-names>G. T.</given-names></name></person-group> (<year>2013</year>). <article-title>Mitochondrial free Ca<sup>2</sup>&#8314; levels and their effects on energy metabolism in Drosophila motor nerve terminals</article-title>. <source>Biophys. J.</source><volume>104</volume>, <fpage>2353</fpage>&#8211;<lpage>2361</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpj.2013.03.064</pub-id><pub-id pub-id-type="pmid">23746507</pub-id><pub-id pub-id-type="pmcid">PMC3672877</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Tanshinone I inhibits doxorubicin-induced cardiotoxicity by regulating Nrf2 signaling pathway</article-title>. <source>Phytomedicine</source><volume>106</volume>, <fpage>154439</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2022.154439</pub-id><pub-id pub-id-type="pmid">36108374</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Stockwell</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Ferroptosis: mechanisms, biology and role in disease</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>22</volume>, <fpage>266</fpage>&#8211;<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-020-00324-8</pub-id><pub-id pub-id-type="pmid">33495651</pub-id><pub-id pub-id-type="pmcid">PMC8142022</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>T.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2022a</year>). <article-title>UAMC-3203 or/and deferoxamine improve post-resuscitation myocardial dysfunction through suppressing ferroptosis in a rat model of cardiac arrest</article-title>. <source>Shock</source><volume>57</volume>, <fpage>344</fpage>&#8211;<lpage>350</lpage>. <pub-id pub-id-type="doi">10.1097/SHK.0000000000001869</pub-id><pub-id pub-id-type="pmid">34618729</pub-id><pub-id pub-id-type="pmcid">PMC8868183</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>P.</given-names></name></person-group> (<year>2022b</year>). <article-title>MiR-125b enhances doxorubicin-induced cardiotoxicity by suppressing the nucleus-cytoplasmic translocation of YAP via targeting STARD13</article-title>. <source>Environ. Toxicol.</source><volume>37</volume>, <fpage>730</fpage>&#8211;<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1002/tox.23438</pub-id><pub-id pub-id-type="pmid">34921586</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansson</surname><given-names>B.</given-names></name></person-group> (<year>1992</year>). <article-title>A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites</article-title>. <source>Acta Psychiatr. Scand. Suppl.</source><volume>369</volume>, <fpage>15</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0447.1992.tb03310.x</pub-id><pub-id pub-id-type="pmid">1471547</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalivendi</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Konorev</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanamala</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Kaji</surname><given-names>E. H.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium</article-title>. <source>Biochem. J.</source><volume>389</volume>, <fpage>527</fpage>&#8211;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20050285</pub-id><pub-id pub-id-type="pmid">15799720</pub-id><pub-id pub-id-type="pmcid">PMC1175131</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kambe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>Zinc transporters and their functional integration in mammalian cells</article-title>. <source>J. Biol. Chem.</source><volume>296</volume>, <fpage>100320</fpage>. <pub-id pub-id-type="doi">10.1016/j.jbc.2021.100320</pub-id><pub-id pub-id-type="pmid">33485965</pub-id><pub-id pub-id-type="pmcid">PMC7949119</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>Y. J.</given-names></name></person-group> (<year>1999</year>). <article-title>The antioxidant function of metallothionein in the heart</article-title>. <source>Proc. Soc. Exp. Biol. Med.</source><volume>222</volume>, <fpage>263</fpage>&#8211;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1046/j.1525-1373.1999.d01-143.x</pub-id><pub-id pub-id-type="pmid">10601885</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Voss-Mccowan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>P. N.</given-names></name></person-group> (<year>1997</year>). <article-title>Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity</article-title>. <source>J. Clin. Invest.</source><volume>100</volume>, <fpage>1501</fpage>&#8211;<lpage>1506</lpage>. <pub-id pub-id-type="doi">10.1172/JCI119672</pub-id><pub-id pub-id-type="pmid">9294117</pub-id><pub-id pub-id-type="pmcid">PMC508330</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z. X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Buridi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J. B.</given-names></name></person-group> (<year>2000</year>). <article-title>Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases</article-title>. <source>J. Biol. Chem.</source><volume>275</volume>, <fpage>13690</fpage>&#8211;<lpage>13698</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.275.18.13690</pub-id><pub-id pub-id-type="pmid">10788488</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W. D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. J.</given-names></name></person-group> (<year>2020</year>). <article-title>TGF-&#946;1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells</article-title>. <source>Cell Death Dis.</source><volume>11</volume>, <fpage>406</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-020-2618-6</pub-id><pub-id pub-id-type="pmid">32471991</pub-id><pub-id pub-id-type="pmcid">PMC7260246</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Rah</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Im</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes</article-title>. <source>Exp. Mol. Med.</source><volume>38</volume>, <fpage>535</fpage>&#8211;<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1038/emm.2006.63</pub-id><pub-id pub-id-type="pmid">17079870</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Viollet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>K. L.</given-names></name></person-group> (<year>2011</year>). <article-title>AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1</article-title>. <source>Nat. Cell Biol.</source><volume>13</volume>, <fpage>132</fpage>&#8211;<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1038/ncb2152</pub-id><pub-id pub-id-type="pmid">21258367</pub-id><pub-id pub-id-type="pmcid">PMC3987946</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Shames</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Woodhouse</surname><given-names>L. R.</given-names></name></person-group> (<year>2000</year>). <article-title>Zinc homeostasis in humans</article-title>. <source>J. Nutr.</source><volume>130</volume>, <fpage>1360S</fpage>&#8211;<lpage>6s</lpage>. <pub-id pub-id-type="doi">10.1093/jn/130.5.1360S</pub-id><pub-id pub-id-type="pmid">10801944</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirschke</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group> (<year>2003</year>). <article-title>ZnT7, a novel mammalian zinc transporter, accumulates zinc in the Golgi apparatus</article-title>. <source>J. Biol. Chem.</source><volume>278</volume>, <fpage>4096</fpage>&#8211;<lpage>4102</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M207644200</pub-id><pub-id pub-id-type="pmid">12446736</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitakata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Endo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ikura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moriyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shirakawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Katsumata</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Therapeutic targets for DOX-induced cardiomyopathy: role of apoptosis vs. Ferroptosis</article-title>. <source>Int. J. Mol. Sci.</source><volume>23</volume>, <fpage>1414</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23031414</pub-id><pub-id pub-id-type="pmid">35163335</pub-id><pub-id pub-id-type="pmcid">PMC8835899</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komatsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sadakata</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ogra</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K. T.</given-names></name></person-group> (<year>2000</year>). <article-title>Excretion of copper complexed with thiomolybdate into the bile and blood in LEC rats</article-title>. <source>Chem. Biol. Interact.</source><volume>124</volume>, <fpage>217</fpage>&#8211;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/s0009-2797(99)00159-3</pub-id><pub-id pub-id-type="pmid">10728780</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krebs</surname><given-names>J.</given-names></name><name name-style="western"><surname>Agellon</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Michalak</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Ca(2+) homeostasis and endoplasmic reticulum (ER) stress: an integrated view of calcium signaling</article-title>. <source>Biochem. Biophys. Res. Commun.</source><volume>460</volume>, <fpage>114</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2015.02.004</pub-id><pub-id pub-id-type="pmid">25998740</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakshmanan</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Harima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Soetikno</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>The hyperglycemia stimulated myocardial endoplasmic reticulum (ER) stress contributes to diabetic cardiomyopathy in the transgenic non-obese type 2 diabetic rats: a differential role of unfolded protein response (UPR) signaling proteins</article-title>. <source>Int. J. Biochem. Cell Biol.</source><volume>45</volume>, <fpage>438</fpage>&#8211;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2012.09.017</pub-id><pub-id pub-id-type="pmid">23032698</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewerenz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hewett</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lambros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gout</surname><given-names>P. W.</given-names></name><name name-style="western"><surname>Kalivas</surname><given-names>P. W.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities</article-title>. <source>Antioxid. Redox Signal</source><volume>18</volume>, <fpage>522</fpage>&#8211;<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2011.4391</pub-id><pub-id pub-id-type="pmid">22667998</pub-id><pub-id pub-id-type="pmcid">PMC3545354</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>J. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Cardiomyocyte autophagy and cancer chemotherapy</article-title>. <source>J. Mol. Cell Cardiol.</source><volume>71</volume>, <fpage>54</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.11.007</pub-id><pub-id pub-id-type="pmid">24239608</pub-id><pub-id pub-id-type="pmcid">PMC4011970</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W. Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Levosimendan protects against doxorubicin-induced cardiotoxicity by regulating the PTEN/Akt pathway</article-title>. <source>Biomed. Res. Int.</source><volume>2020</volume>, <fpage>8593617</fpage>. <pub-id pub-id-type="doi">10.1155/2020/8593617</pub-id><pub-id pub-id-type="pmid">32596387</pub-id><pub-id pub-id-type="pmcid">PMC7298255</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name></person-group> (<year>2022a</year>). <article-title>ROS and iron homeostasis dependent ferroptosis play a vital role in 5-Fluorouracil induced cardiotoxicity <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>
</article-title>. <source>Toxicology</source><volume>468</volume>, <fpage>153113</fpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2022.153113</pub-id><pub-id pub-id-type="pmid">35101590</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name></person-group> (<year>2019</year>). <article-title>miR-451 silencing inhibited doxorubicin exposure-induced cardiotoxicity in mice</article-title>. <source>Biomed. Res. Int.</source><volume>2019</volume>, <fpage>1528278</fpage>. <pub-id pub-id-type="doi">10.1155/2019/1528278</pub-id><pub-id pub-id-type="pmid">31355248</pub-id><pub-id pub-id-type="pmcid">PMC6637715</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury</article-title>. <source>Free Radic. Biol. Med.</source><volume>160</volume>, <fpage>303</fpage>&#8211;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.08.009</pub-id><pub-id pub-id-type="pmid">32846217</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>He</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sunkara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>AMPK inhibits the stimulatory effects of TGF-&#946; on smad2/3 activity, cell migration, and epithelial-to-mesenchymal transition</article-title>. <source>Mol. Pharmacol.</source><volume>88</volume>, <fpage>1062</fpage>&#8211;<lpage>1071</lpage>. <pub-id pub-id-type="doi">10.1124/mol.115.099549</pub-id><pub-id pub-id-type="pmid">26424816</pub-id><pub-id pub-id-type="pmcid">PMC4658597</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>LCZ696 protects against doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via AKT/SIRT3/SOD2 signaling pathway activation</article-title>. <source>Int. Immunopharmacol.</source><volume>113</volume>, <fpage>109379</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2022.109379</pub-id><pub-id pub-id-type="pmid">36330913</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name></person-group> (<year>2022b</year>). <article-title>PEX1 is a mediator of &#945;1-adrenergic signaling attenuating doxorubicin-induced cardiotoxicity</article-title>. <source>J. Biochem. Mol. Toxicol.</source><volume>36</volume>, <fpage>e23196</fpage>. <pub-id pub-id-type="doi">10.1002/jbt.23196</pub-id><pub-id pub-id-type="pmid">35979984</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2022c</year>). <article-title>Protective effect of Di'ao Xinxuekang capsule against doxorubicin-induced chronic cardiotoxicity</article-title>. <source>J. Ethnopharmacol.</source><volume>287</volume>, <fpage>114943</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2021.114943</pub-id><pub-id pub-id-type="pmid">34954266</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020c</year>). <article-title>Disulfiram/copper induces antitumor activity against both nasopharyngeal cancer cells and cancer-associated fibroblasts through ROS/MAPK and ferroptosis pathways</article-title>. <source>Cancers (Basel)</source><volume>12</volume>, <fpage>138</fpage>. <pub-id pub-id-type="doi">10.3390/cancers12010138</pub-id><pub-id pub-id-type="pmid">31935835</pub-id><pub-id pub-id-type="pmcid">PMC7017005</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name></person-group> (<year>2023</year>). <article-title>Isoquercitrin promotes ferroptosis and oxidative stress in nasopharyngeal carcinoma via the AMPK/NF-&#954;B pathway</article-title>. <source>J. Biochem. Mol. Toxicol.</source>, <fpage>e23542</fpage>. <pub-id pub-id-type="doi">10.1002/jbt.23542</pub-id><pub-id pub-id-type="pmid">37712196</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mammoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Panigrahy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kieran</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Mammoto</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression</article-title>. <source>Am. J. Pathol.</source><volume>183</volume>, <fpage>1293</fpage>&#8211;<lpage>1305</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2013.06.026</pub-id><pub-id pub-id-type="pmid">23928381</pub-id><pub-id pub-id-type="pmcid">PMC3791684</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pellei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tisato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Santini</surname><given-names>C.</given-names></name></person-group> (<year>2009</year>). <article-title>Copper complexes as anticancer agents</article-title>. <source>Anticancer Agents Med. Chem.</source><volume>9</volume>, <fpage>185</fpage>&#8211;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.2174/187152009787313837</pub-id><pub-id pub-id-type="pmid">19199864</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matikainen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pekkarinen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ryhanen</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Schalin-Jantti</surname><given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Physiology of calcium homeostasis: an overview</article-title>. <source>Endocrinol. Metab. Clin. North Am.</source><volume>50</volume>, <fpage>575</fpage>&#8211;<lpage>590</lpage>. <pub-id pub-id-type="doi">10.1016/j.ecl.2021.07.005</pub-id><pub-id pub-id-type="pmid">34774235</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meloni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zovo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kazantseva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Palumaa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vas&#225;K</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Organization and assembly of metal-thiolate clusters in epithelium-specific metallothionein-4</article-title>. <source>J. Biol. Chem.</source><volume>281</volume>, <fpage>14588</fpage>&#8211;<lpage>14595</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M601724200</pub-id><pub-id pub-id-type="pmid">16556599</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Reduced serum zinc ion concentration is associated with coronary heart disease</article-title>. <source>Biol. Trace Elem. Res.</source><volume>199</volume>, <fpage>4109</fpage>&#8211;<lpage>4118</lpage>. <pub-id pub-id-type="doi">10.1007/s12011-020-02551-8</pub-id><pub-id pub-id-type="pmid">33387273</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menon</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>Iron promotes cardiac doxorubicin retention and toxicity through downregulation of the mitochondrial exporter ABCB8</article-title>. <source>Front. Pharmacol.</source><volume>13</volume>, <fpage>817951</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.817951</pub-id><pub-id pub-id-type="pmid">35359834</pub-id><pub-id pub-id-type="pmcid">PMC8963208</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitry</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J. G.</given-names></name></person-group> (<year>2016</year>). <article-title>Doxorubicin induced heart failure: phenotype and molecular mechanisms</article-title>. <source>Int. J. Cardiol. Heart Vasc.</source><volume>10</volume>, <fpage>17</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcha.2015.11.004</pub-id><pub-id pub-id-type="pmid">27213178</pub-id><pub-id pub-id-type="pmcid">PMC4871279</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizutani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hiraku</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Murata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kojima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawanishi</surname><given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>Distinct mechanisms of site-specific oxidative DNA damage by doxorubicin in the presence of copper(II) and NADPH-cytochrome P450 reductase</article-title>. <source>Cancer Sci.</source><volume>94</volume>, <fpage>686</fpage>&#8211;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2003.tb01503.x</pub-id><pub-id pub-id-type="pmid">12901793</pub-id><pub-id pub-id-type="pmcid">PMC11160291</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mughal</surname><given-names>W.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Field</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rattan</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Myocardin regulates mitochondrial calcium homeostasis and prevents permeability transition</article-title>. <source>Cell Death Differ.</source><volume>25</volume>, <fpage>1732</fpage>&#8211;<lpage>1748</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-018-0073-z</pub-id><pub-id pub-id-type="pmid">29511336</pub-id><pub-id pub-id-type="pmcid">PMC6180099</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukhopadhyay</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rajesh</surname><given-names>M.</given-names></name><name name-style="western"><surname>B&#225;TKAI</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kashiwaya</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hask&#243;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liaudet</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic>
</article-title>. <source>Am. J. Physiol. Heart Circ. Physiol.</source><volume>296</volume>, <fpage>H1466</fpage>&#8211;<lpage>H1483</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00795.2008</pub-id><pub-id pub-id-type="pmid">19286953</pub-id><pub-id pub-id-type="pmcid">PMC2685360</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tatsumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shiraishi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mano</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Nicorandil regulates Bcl-2 family proteins and protects cardiac myocytes against hypoxia-induced apoptosis</article-title>. <source>J. Mol. Cell Cardiol.</source><volume>40</volume>, <fpage>510</fpage>&#8211;<lpage>519</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2006.01.020</pub-id><pub-id pub-id-type="pmid">16527305</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olgar</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Durak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tuncay</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bitirim</surname><given-names>C. V.</given-names></name><name name-style="western"><surname>Ozcinar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Inan</surname><given-names>M. B.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Increased free Zn(2+) correlates induction of sarco(endo)plasmic reticulum stress via altered expression levels of Zn(2+) -transporters in heart failure</article-title>. <source>J. Cell Mol. Med.</source><volume>22</volume>, <fpage>1944</fpage>&#8211;<lpage>1956</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13480</pub-id><pub-id pub-id-type="pmid">29333637</pub-id><pub-id pub-id-type="pmcid">PMC5824399</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olson</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>W. D.</given-names></name><name name-style="western"><surname>Mccall</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Ilstrup</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Gersh</surname><given-names>B. J.</given-names></name></person-group> (<year>1987</year>). <article-title>Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy</article-title>. <source>J. Am. Coll. Cardiol.</source><volume>10</volume>, <fpage>1239</fpage>&#8211;<lpage>1243</lpage>. <pub-id pub-id-type="doi">10.1016/s0735-1097(87)80124-9</pub-id><pub-id pub-id-type="pmid">3680791</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panjrath</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>V.</given-names></name><name name-style="western"><surname>Valdiviezo</surname><given-names>C. I.</given-names></name><name name-style="western"><surname>Narula</surname><given-names>N.</given-names></name><name name-style="western"><surname>Narula</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model</article-title>. <source>J. Am. Coll. Cardiol.</source><volume>49</volume>, <fpage>2457</fpage>&#8211;<lpage>2464</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2007.02.060</pub-id><pub-id pub-id-type="pmid">17599610</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L. W.</given-names></name><name name-style="western"><surname>Merajver</surname><given-names>S. D.</given-names></name></person-group> (<year>2003</year>). <article-title>Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade</article-title>. <source>Mol. Cancer Res.</source><volume>1</volume>, <fpage>701</fpage>&#8211;<lpage>706</lpage>.<pub-id pub-id-type="pmid">12939395</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pivetta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lallai</surname><given-names>V.</given-names></name><name name-style="western"><surname>Valletta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Trudu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Isaia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Perra</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Mixed copper-platinum complex formation could explain synergistic antiproliferative effect exhibited by binary mixtures of cisplatin and copper-1,10-phenanthroline compounds: an ESI-MS study</article-title>. <source>J. Inorg. Biochem.</source><volume>151</volume>, <fpage>107</fpage>&#8211;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2015.05.004</pub-id><pub-id pub-id-type="pmid">26021964</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollesello</surname><given-names>P.</given-names></name><name name-style="western"><surname>Papp</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Papp</surname><given-names>J. G.</given-names></name></person-group> (<year>2016</year>). <article-title>Calcium sensitizers: what have we learned over the last 25 years?</article-title><source>Int. J. Cardiol.</source><volume>203</volume>, <fpage>543</fpage>&#8211;<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2015.10.240</pub-id><pub-id pub-id-type="pmid">26580334</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purchase</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>The link between copper and Wilson's disease</article-title>. <source>Sci. Prog.</source><volume>96</volume>, <fpage>213</fpage>&#8211;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.3184/003685013X13712193905878</pub-id><pub-id pub-id-type="pmid">24244969</pub-id><pub-id pub-id-type="pmcid">PMC10365353</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quagliariello</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Laurentiis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rea</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barbieri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monti</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin</article-title>. <source>Cardiovasc Diabetol.</source><volume>20</volume>, <fpage>150</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-021-01346-y</pub-id><pub-id pub-id-type="pmid">34301253</pub-id><pub-id pub-id-type="pmcid">PMC8305868</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Gasdermin D mediates endoplasmic reticulum stress via FAM134B to regulate cardiomyocyte autophagy and apoptosis in doxorubicin-induced cardiotoxicity</article-title>. <source>Cell Death Dis.</source><volume>13</volume>, <fpage>901</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-022-05333-3</pub-id><pub-id pub-id-type="pmid">36289195</pub-id><pub-id pub-id-type="pmcid">PMC9606128</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Refaie</surname><given-names>M. M. M.</given-names></name><name name-style="western"><surname>Shehata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Bayoumi</surname><given-names>A. M. A.</given-names></name><name name-style="western"><surname>Abdel-Gaber</surname><given-names>S. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Dose-dependent cardioprotective effect of hemin in doxorubicin-induced cardiotoxicity via nrf-2/HO-1 and TLR-5/NF-&#954;B/TNF-&#945; signaling pathways</article-title>. <source>Cardiovasc Toxicol.</source><volume>21</volume>, <fpage>1033</fpage>&#8211;<lpage>1044</lpage>. <pub-id pub-id-type="doi">10.1007/s12012-021-09694-7</pub-id><pub-id pub-id-type="pmid">34510376</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Permissive role of AMPK and autophagy in adiponectin deficiency-accentuated myocardial injury and inflammation in endotoxemia</article-title>. <source>J. Mol. Cell Cardiol.</source><volume>93</volume>, <fpage>18</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2016.02.002</pub-id><pub-id pub-id-type="pmid">26906634</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abilash</surname><given-names>V. G.</given-names></name><name name-style="western"><surname>Tirupathi Pichiah</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Molecular mechanism of doxorubicin-induced cardiomyopathy - an update</article-title>. <source>Eur. J. Pharmacol.</source><volume>818</volume>, <fpage>241</fpage>&#8211;<lpage>253</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2017.10.043</pub-id><pub-id pub-id-type="pmid">29074412</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schimmer</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Jitkova</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gronda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Brandwein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies</article-title>. <source>Clin. Lymphoma Myeloma Leuk.</source><volume>12</volume>, <fpage>330</fpage>&#8211;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1016/j.clml.2012.05.005</pub-id><pub-id pub-id-type="pmid">22683301</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheibani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Azizi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shayan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nezamoleslami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eslami</surname><given-names>F.</given-names></name><name name-style="western"><surname>Farjoo</surname><given-names>M. H.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Doxorubicin-induced cardiotoxicity: an overview on pre-clinical therapeutic approaches</article-title>. <source>Cardiovasc Toxicol.</source><volume>22</volume>, <fpage>292</fpage>&#8211;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1007/s12012-022-09721-1</pub-id><pub-id pub-id-type="pmid">35061218</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name></person-group> (<year>2022</year>). <article-title>Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2 cells</article-title>. <source>Int. J. Mol. Med.</source><volume>12</volume>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2021.5072</pub-id><pub-id pub-id-type="pmcid">PMC8711589</pub-id><pub-id pub-id-type="pmid">34935058</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart</article-title>. <source>Cancer Res.</source><volume>61</volume>, <fpage>3382</fpage>&#8211;<lpage>3387</lpage>.<pub-id pub-id-type="pmid">11309296</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swain</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Whaley</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>M. S.</given-names></name></person-group> (<year>2003</year>). <article-title>Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials</article-title>. <source>Cancer</source><volume>97</volume>, <fpage>2869</fpage>&#8211;<lpage>2879</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.11407</pub-id><pub-id pub-id-type="pmid">12767102</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Syamprasad</surname><given-names>N. P.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rajdev</surname><given-names>B.</given-names></name><name name-style="western"><surname>Panda</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Gangasani</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Challa</surname><given-names>V. S.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>AKR1B1 inhibition using NARI-29-an Epalrestat analogue-alleviates Doxorubicin-induced cardiotoxicity via modulating Calcium/CaMKII/MuRF-1 axis</article-title>. <source>Chem. Biol. Interact.</source><volume>381</volume>, <fpage>110566</fpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2023.110566</pub-id><pub-id pub-id-type="pmid">37257577</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tadokoro</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ide</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity</article-title>. <source>JCI Insight</source><volume>5</volume>, <fpage>e132747</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.132747</pub-id><pub-id pub-id-type="pmid">32376803</pub-id><pub-id pub-id-type="pmcid">PMC7253028</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tainer</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Getzoff</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>D. C.</given-names></name></person-group> (<year>1983</year>). <article-title>Structure and mechanism of copper, zinc superoxide dismutase</article-title>. <source>Nature</source><volume>306</volume>, <fpage>284</fpage>&#8211;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1038/306284a0</pub-id><pub-id pub-id-type="pmid">6316150</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Bachowski</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Girotti</surname><given-names>A. W.</given-names></name></person-group> (<year>1986</year>). <article-title>Inhibition of cell membrane lipid peroxidation by cadmium- and zinc-metallothioneins</article-title>. <source>Biochim. Biophys. Acta</source><volume>884</volume>, <fpage>448</fpage>&#8211;<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1016/0304-4165(86)90195-9</pub-id><pub-id pub-id-type="pmid">3778934</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townsend</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Tew</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Tapiero</surname><given-names>H.</given-names></name></person-group> (<year>2003</year>). <article-title>The importance of glutathione in human disease</article-title>. <source>Biomed. Pharmacother.</source><volume>57</volume>, <fpage>145</fpage>&#8211;<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1016/s0753-3322(03)00043-x</pub-id><pub-id pub-id-type="pmid">12818476</pub-id><pub-id pub-id-type="pmcid">PMC6522248</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuncay</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bitirim</surname><given-names>C. V.</given-names></name><name name-style="western"><surname>Olgar</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Durak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rutter</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Turan</surname><given-names>B.</given-names></name></person-group> (<year>2019</year>). <article-title>Zn(2+)-transporters ZIP7 and ZnT7 play important role in progression of cardiac dysfunction via affecting sarco(endo)plasmic reticulum-mitochondria coupling in hyperglycemic cardiomyocytes</article-title>. <source>Mitochondrion</source><volume>44</volume>, <fpage>41</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.mito.2017.12.011</pub-id><pub-id pub-id-type="pmid">29307859</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuncay</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bitirim</surname><given-names>V. C.</given-names></name><name name-style="western"><surname>Durak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carrat</surname><given-names>G. R. J.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Rutter</surname><given-names>G. A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Hyperglycemia-induced changes in ZIP7 and ZnT7 expression cause Zn(2+) release from the sarco(endo)plasmic reticulum and mediate ER stress in the heart</article-title>. <source>Diabetes</source><volume>66</volume>, <fpage>1346</fpage>&#8211;<lpage>1358</lpage>. <pub-id pub-id-type="doi">10.2337/db16-1099</pub-id><pub-id pub-id-type="pmid">28232492</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turan</surname><given-names>B.</given-names></name></person-group> (<year>2019</year>). <article-title>A brief overview from the physiological and detrimental roles of zinc homeostasis via zinc transporters in the heart</article-title>. <source>Biol. Trace Elem. Res.</source><volume>188</volume>, <fpage>160</fpage>&#8211;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1007/s12011-018-1464-1</pub-id><pub-id pub-id-type="pmid">30091070</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uzel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>M. E.</given-names></name></person-group> (<year>1998</year>). <article-title>Absorption of heme iron</article-title>. <source>Semin. Hematol.</source><volume>35</volume>, <fpage>27</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">9460807</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2022a</year>). <article-title>Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2</article-title>. <source>Redox Biol.</source><volume>52</volume>, <fpage>102310</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2022.102310</pub-id><pub-id pub-id-type="pmid">35452917</pub-id><pub-id pub-id-type="pmcid">PMC9043985</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>298</volume>, <fpage>461</fpage>&#8211;<lpage>468</lpage>.<pub-id pub-id-type="pmid">11454906</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>ATF3 promotes erastin-induced ferroptosis by suppressing system Xc<sup>-</sup>
</article-title>. <source>Cell Death Differ.</source><volume>27</volume>, <fpage>662</fpage>&#8211;<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-019-0380-z</pub-id><pub-id pub-id-type="pmid">31273299</pub-id><pub-id pub-id-type="pmcid">PMC7206049</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y. L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X. Z.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y. G.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>X. R.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Current understanding of metal ions in the pathogenesis of Alzheimer's disease</article-title>. <source>Transl. Neurodegener.</source><volume>9</volume>, <fpage>10</fpage>. <pub-id pub-id-type="doi">10.1186/s40035-020-00189-z</pub-id><pub-id pub-id-type="pmid">32266063</pub-id><pub-id pub-id-type="pmcid">PMC7119290</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Men</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022b</year>). <article-title>Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways</article-title>. <source>Acta Pharm. Sin. B</source><volume>12</volume>, <fpage>708</fpage>&#8211;<lpage>722</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2021.10.005</pub-id><pub-id pub-id-type="pmid">35256941</pub-id><pub-id pub-id-type="pmcid">PMC8897044</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Su</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Berberine alleviates doxorubicin-induced myocardial injury and fibrosis by eliminating oxidative stress and mitochondrial damage via promoting nrf-2 pathway activation</article-title>. <source>Int. J. Mol. Sci.</source><volume>24</volume>, <fpage>3257</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24043257</pub-id><pub-id pub-id-type="pmid">36834687</pub-id><pub-id pub-id-type="pmcid">PMC9966753</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Taurine zinc solid dispersions attenuate doxorubicin-induced hepatotoxicity and cardiotoxicity in rats</article-title>. <source>Toxicol. Appl. Pharmacol.</source><volume>289</volume>, <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2015.08.017</pub-id><pub-id pub-id-type="pmid">26335259</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2022c</year>). <article-title>PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway</article-title>. <source>Cell Death Differ.</source><volume>29</volume>, <fpage>1982</fpage>&#8211;<lpage>1995</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-022-00990-5</pub-id><pub-id pub-id-type="pmid">35383293</pub-id><pub-id pub-id-type="pmcid">PMC9525272</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2022d</year>). <article-title>Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3&#946;/Nrf2 axis</article-title>. <source>Biomed. Pharmacother.</source><volume>154</volume>, <fpage>113572</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.113572</pub-id><pub-id pub-id-type="pmid">35988428</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>G.</given-names></name><name name-style="western"><surname>Loyevsky</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gordeuk</surname><given-names>V. R.</given-names></name></person-group> (<year>1999</year>). <article-title>Dexrazoxane (ICRF-187)</article-title>. <source>Gen. Pharmacol.</source><volume>32</volume>, <fpage>155</fpage>&#8211;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1016/s0306-3623(98)00100-1</pub-id><pub-id pub-id-type="pmid">9888268</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>QiShenYiQi dripping pill alleviates myocardial ischemia-induced ferroptosis via improving mitochondrial dynamical homeostasis and biogenesis</article-title>. <source>J. Ethnopharmacol.</source><volume>308</volume>, <fpage>116282</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2023.116282</pub-id><pub-id pub-id-type="pmid">36806343</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Zn(ii)-Curcumin supplementation alleviates gut dysbiosis and zinc dyshomeostasis during doxorubicin-induced cardiotoxicity in rats</article-title>. <source>Food Funct.</source><volume>10</volume>, <fpage>5587</fpage>&#8211;<lpage>5604</lpage>. <pub-id pub-id-type="doi">10.1039/c9fo01034c</pub-id><pub-id pub-id-type="pmid">31432062</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>ADAR2 increases in exercised heart and protects against myocardial infarction and doxorubicin-induced cardiotoxicity</article-title>. <source>Mol. Ther.</source><volume>30</volume>, <fpage>400</fpage>&#8211;<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2021.07.004</pub-id><pub-id pub-id-type="pmid">34274534</pub-id><pub-id pub-id-type="pmcid">PMC8753375</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification</article-title>. <source>Kidney Int.</source><volume>102</volume>, <fpage>1259</fpage>&#8211;<lpage>1275</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2022.07.034</pub-id><pub-id pub-id-type="pmid">36063875</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshii</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yoshiji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kuriyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ikenaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells</article-title>. <source>Int. J. Cancer</source><volume>94</volume>, <fpage>768</fpage>&#8211;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.1537</pub-id><pub-id pub-id-type="pmid">11745476</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaidi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arjmand</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zaidi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Usmani</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Zubair</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akhtar</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A comprehensive biological insight of trinuclear copper(II)-tin(IV) chemotherapeutic anticancer drug entity: <italic toggle="yes">in vitro</italic> cytotoxicity and <italic toggle="yes">in vivo</italic> systemic toxicity studies</article-title>. <source>Metallomics</source><volume>6</volume>, <fpage>1469</fpage>&#8211;<lpage>1479</lpage>. <pub-id pub-id-type="doi">10.1039/c4mt00035h</pub-id><pub-id pub-id-type="pmid">24817323</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W. B.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X. F.</given-names></name></person-group> (<year>2021</year>). <article-title>Activation of Nrf2 by miR-152 inhibits doxorubicin-induced cardiotoxicity via attenuation of oxidative stress, inflammation, and apoptosis</article-title>. <source>Oxid. Med. Cell Longev.</source><volume>2021</volume>, <fpage>8860883</fpage>. <pub-id pub-id-type="doi">10.1155/2021/8860883</pub-id><pub-id pub-id-type="pmid">33574984</pub-id><pub-id pub-id-type="pmcid">PMC7857911</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>An</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2023a</year>). <article-title>Qing-Xin-Jie-Yu Granule inhibits ferroptosis and stabilizes atherosclerotic plaques by regulating the GPX4/xCT signaling pathway</article-title>. <source>J. Ethnopharmacol.</source><volume>301</volume>, <fpage>115852</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2022.115852</pub-id><pub-id pub-id-type="pmid">36272494</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Long</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2023b</year>). <article-title>Curative effect of zinc-selenium tea on rat's cardiotoxicity induced by long-term exposure to nonylphenol</article-title>. <source>Environ. Toxicol.</source><volume>38</volume>, <fpage>101</fpage>&#8211;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1002/tox.23667</pub-id><pub-id pub-id-type="pmid">36239032</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Ferroptosis in cancer and cancer immunotherapy</article-title>. <source>Cancer Commun. (Lond)</source><volume>42</volume>, <fpage>88</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1002/cac2.12250</pub-id><pub-id pub-id-type="pmid">35133083</pub-id><pub-id pub-id-type="pmcid">PMC8822596</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>MicroRNA-128-3p aggravates doxorubicin-induced liver injury by promoting oxidative stress via targeting Sirtuin-1</article-title>. <source>Pharmacol. Res.</source><volume>146</volume>, <fpage>104276</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2019.104276</pub-id><pub-id pub-id-type="pmid">31112750</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name></person-group> (<year>2021</year>). <article-title>Cardiomyocyte Stim1 deficiency exacerbates doxorubicin cardiotoxicity by magnification of endoplasmic reticulum stress</article-title>. <source>J. Inflamm. Res.</source><volume>14</volume>, <fpage>3945</fpage>&#8211;<lpage>3958</lpage>. <pub-id pub-id-type="doi">10.2147/JIR.S304520</pub-id><pub-id pub-id-type="pmid">34421306</pub-id><pub-id pub-id-type="pmcid">PMC8373307</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoroddu</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Aaseth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Crisponi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Medici</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nurchi</surname><given-names>V. M.</given-names></name></person-group> (<year>2019</year>). <article-title>The essential metals for humans: a brief overview</article-title>. <source>J. Inorg. Biochem.</source><volume>195</volume>, <fpage>120</fpage>&#8211;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinorgbio.2019.03.013</pub-id><pub-id pub-id-type="pmid">30939379</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>